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ACTIVATING THE 4-1BB PATHWAY FOR THE EXPANSION OF TUMORINFILTRATING LYMPHOCYTES FOR ADOPTIVE T-CELL THERAPY
FOR METASTATIC MELANOMA PATIENTS

Jessica Ann Chacon, M.S.
Supervisory Professor: Laszlo Radvanyi, PhD
This dissertation project focused on improving the quality of the tumorinfiltrating lymphocytes (TIL) used in Adoptive T-cell therapy by understanding the
role of 4-1BB/CD137 co-stimulation during the expansion of the tumor-infiltrating
lymphocytes (TIL). Adoptive T-cell therapy using TIL is a promising therapy for late
stage melanoma patients, resulting in a 50% response rate and durable long-term
survival in over 20% of patients. Current research is aiming at improving the quality
of the expanded cells and their persistence in vivo after adoptive transfer to further
boost response rates. The specific focus of this dissertation project is the testing of
agonistic anti-4-1BB antibodies at different stages of TIL expansion from tumors for
its effects on modulating the phenotype and anti-tumor activity of the cells. The
expansion of TIL from the melanoma tumor occurs in 2 stages: The first stage
involves the initial expansion of the TIL from small cut 3-5 mm2 fragments of viable
tumor (12-24 fragments/tumor) with Interleukin-2 (IL-2) over a 4-5 week period; TIL
isolated after this stage are referred to as ‘pre-REP’ TIL. The second stage involves
the pre-REP TIL undergoing a secondary expansion referred to as the rapid expansion
protocol (REP) for a period of 2 weeks in which the TIL are activated through the Tcell receptor (TCR) and also provided IL-2 to trigger rapid cell division. The TIL are
then referred to as ‘post-REP’ TIL after this expansion. We have found that 4-1BB is
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expressed on freshly isolated T cells that are within melanoma tumor fragments, as
well as expressed on pre- and post- REP TIL. This observation prompted us to
investigate what the role of 4-1BB ligation would play during the expansion of the
TIL. We demonstrated that providing co-stimulation to the TIL during the initial
expansion stage and during the secondary expansion using an agonist anti-4-1BB
antibody facilitated an increased expansion of CD8+ TIL with increased cytolytic
function and a phenotype of memory T cells with enhanced cell survival gene
expression. TIL receiving 4-1BB co-stimulation during expansion also exhibited
longer persistence and increased anti-tumor activity in an in vivo human TIL adoptive
transfer model using NOD-SCID-gamma chain-/- (NSG) mice xenografted with HLAA-matched melanoma cells. The post-REP TIL also exhibited improved responses to
antigenic re-stimulation when the anti-4-1BB antibody was added during expansion.
We also investigated the role of 4-1BB ligation in the tumor
microenvironment ex vivo in the tumor fragments used as the source of the expanded
TIL. We found that in addition to 4-1BB being expressed on T cells in these
fragments 4-1BB was also expressed on dendritic cells within the melanoma tumor
fragments. Addition of agonist anti-4-1BB increased activation and NFκB (a key
marker of 4-1BB signaling) in these dendritic cells and T cells, that was associated
with the increased proliferation and activation state of the CD8+ T cells growing out
of these fragments. Moreover, 4-1BB co-stimulation in these early tumor fragment
cultures also significantly enriched the tumor specificity of the TIL, as found by an
increase in the frequency of tumor-specific CD8+ T cells in single cell and bulk antitumor reactivity assays.
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In conclusion, our results demonstrate that enhancing 4-1BB co-stimulation at
different stages of melanoma TIL expansion ex vivo increases the CD8+ TIL yield,
greatly increases tumor specificity, and enhances the effector-memory phenotype of
the cells conducive to improved persistence and anti-tumor activity in vivo during
adoptive cell therapy. Our results indicate that addition of an anti-4-1BB antibody
during the initial and/or secondary expansion of the TIL in the clinic we will result in
a significantly enhanced TIL product than with currently used expansion protocols
that will boost clinical response rates and durable long-term survival in treated
patients.
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CHAPTER 1

General Introduction
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1.1 Melanoma
There are 3 different types of skin cancer; basal cell carcinoma, squamous cell
carcinoma, and melanoma (1). Melanoma is the deadliest type of skin cancer due to
its metastatic behavior. The origin of melanoma starts in the melanocytes. Cancerous
cells develop as a result of mutations that develop in the DNA of the melanocytes (1).
Mutations can occur due to DNA damage (often caused by ultraviolet radiation) that
has not been repaired (1). The four types of melanoma are superficial spreading
melanoma, lentigo maligna, acral lentiginous, and nodula melanoma (1). Superficial
spreading melanoma is the most common form of melanoma and accounts for 70% of
all cases (1). Lentigo maligna is the most common form of melanoma in Hawaii.
Acral lentiginous usually appears on the soles of the feet, palms of hands and under
the nails, and is most commonly seen in the African Americans, Asian and Hispanic
populations. Unlike the other types, which first appear on the surface of the skin and
then later become invasive, nodular melanoma is invasive at first diagnosis and is the
most aggressive form of melanoma (1).
Melanoma has different stages (Figure 1.1), the earlier the stage of detection,
the better survival rate. Stage 0 melanoma tumors are confined to the epidermis of the
skin and can be treated through surgically removing the tumor. Stage I (A and B) is
defined by the tumor being less than 1 millimeter and treated through surgery. In
stage IA, the tumor is not ulcerated, and stage IB, the tumor is ulcerated (1). Stage II
(A B, C) is when the tumor is 1-4 millimeters thick and treated using surgery (stage
IIA, the tumor is between 1.01mm and 2.0mm and ulcerated or if the tumor is
between 2.01 and 4.0mm and not ulcerated (1). In stage IIB, the tumor is between 2-
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4mm thick with ulceration, or more than 4mm thick with no ulceration. In stage IIC,
the tumor is more than 4 millimeters thick and ulcerated, surgery, as well as
additional treatment may be necessary (1). In stage III (A-C) melanoma, the tumor is
more independent of thickness and more dependent on the ability to spread to nearby
tissue and/or lymph nodes. In stage IIIA, the tumor is any thickness, not ulcerated,
and spread to 1-3 nearby lymph nodes (1). Stage IIIB, the tumor is any thickness, has
spread to nearby lymph nodes, and the lymph nodes are enlarged (1). In stage IIIC,
the melanoma has spread to 4 or more lymph nodes, is ulcerated, and lymph nodes
are enlarged. Treatment is surgery, as well as targeted therapy or immunotherapy.
Stage IV (metastatic melanoma) is the most serious stage because the cancer has
spread beyond the lymph nodes, as well as metastasized to other organs of the body
(lung, liver, brain, distant areas of skin or distant lymph nodes) (1). The treatment
involves surgery, targeted therapy, and immunotherapy.
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Figure 1.1. Characteristics of the different stages of melanoma. The different
stages of melanoma (0-IV) differ in their size, location within the skin, patient
survival rate, treatment, and the ability to metastasize. The later the stage of
melanoma, the harder the disease is to treat. Surgery is the primary treatment, but in
later stages of melanoma, surgery, as well as other forms of therapy, such as
chemotherapy, radiation, and even immunotherapy may be needed.
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Figure 1.1. Characteristics of the different stages of melanoma.
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Surgery,
Immunotherapy,
Targeted
Therapy
15-20%

It is estimated, according to the American Cancer Society, that in 2014, there
will be 43, 890 new cases of skin melanoma in men and 32, 210 new cases of skin
melanoma in women, and 9,710 people will die from this disease. Melanoma is a
growing epidemic in the U.S. as one in fifty people has a risk of getting diagnosed
with melanoma in their lifetime, someone will be diagnosed with melanoma every
eight minutes and melanoma will kill someone every hour of every single day.
Therefore, it is especially crucial that innovative treatments be developed and
current treatments become more effective in treating melanoma. Dacarbazine has
been the traditional chemotherapy treatment for metastatic melanoma. However, due
to the vastly transient nature of tumor relapses occurring, treating melanoma using
dacarbazine does not have major impacts on patient overall survival. Cancer cells are
highly resistant to cytostatic agents and radiation. One of the newer hallmarks of
cancer is avoiding immune destruction, therefore, novel therapeutics that utilize the
immune system, such as immunotherapeutic agents and techniques have been
developed. These will be described in the next section.
1.2 Immunotherapy
Attempts to augment the immune system to treat cancer began over a century
ago. In the 19th and 20th century, bacteria were injected into tumor-bearing individuals
in studies mainly conducted by Coley (2-6). This work was later extended to include
treatment of tumor-bearing individuals with injected killed bacteria into the tumor
and eradication of the tumor was a result of Tumor Necrosis Factor (TNF) production
in response to the bacterial endotoxins (2-6).
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In 1926, J.B. Murphy proposed that lymphoid cells played a key role in
eradicating solid tumors that had previously been transplanted in animal models (7).
In 1958, Sir Peter Medawar coined the term “immunological competent cell” to
describe a cell that is “fully qualified to undertake an immunological response (7, 8).”
In the mid-1960s, Alexander and associates treated mice that had sarcomas using
lymphocytes from immunized syngeneic animals (8, 9). Alex Fefer and colleagues
demonstrated in 1969 that mice containing lymphomas that were virally induced
could be treated using chemotherapy and infusion of lymphocytes (10, 11). In the
mid-1970s, Eberlein and colleagues demonstrated that immune cells could be
expanded using the growth factor Interleukin-2 (IL-2), be injected intravenously into
a tumor-bearing mice and eradicate the implanted tumors (11-15). In the early 1990s,
Boon and colleagues discovered (from MAGE-3) the first tumor-associated Human
Leukocyte Antigen (HLA)-restricted T-cell epitope (16). A timeline of some of these
major Immunotherapy breakthroughs is demonstrated in Figure 1.2.
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Figure 1.2. The long and winding road of Immunotherapy. Immunotherapy began
over a century ago. Experiments to eradicate tumors using the immune system lead
researchers to develop innovative approaches to modify the immune system to treat
cancer.
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Figure 1.2. The long and winding road of Immunotherapy.
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Genetically modified autologous peripheral blood
lymphocytes expressing TCR that recoginzes MART-1 or
gp100 used to treat melanoma patients (2006)

The immune system is our first line of defense to help protect us from foreign
pathogens. Knowledge regarding the immune system has greatly increased over the
years, paving the way for immunotherapy to become a novel way to treat diseases,
including cancer. Many cancer cells become resistant to conventional therapy, such as
chemotherapy and radiation, resulting in many patients relapsing, therefore
immunotherapies have been developed to overcome this resistance (11, 17-19).
Passive and active immunotherapies have been developed over the years (Table 1).
Passive immunotherapies consist of antibodies, cytokines or other elements of the
immune system that are constructed in a laboratory and subsequently administered to
patients to provide immunity against a disease. On the other hand, active
immunotherapy involves the direct stimulation of the host immune system, usually
through the use of vaccines. Table 1 lists different types of immunotherapies that are
branched into either passive or active forms.
TABLE 1. Types of Immunotherapy

TYPES OF IMMUNOTHERAPY
PASSIVE
Humanized monoclonal antibodies:
 Anti-CD19 (Rituximab)
 Anti-HER2/neu (Herceptin)
 Anti-CTLA4
Adoptive T-cell Therapy:
 TILs
 TCR-transduced
 CAR transduced
Cytokines and immune modulators:
 IL-2
 IFN-alpha
 TLR ligands (CpG, Poly I:C)
 Anti-CTLA-4
 PD-1/PDL-1

ACTIVE
Antigen-specific cancer vaccines:
 Peptide vaccine
 Viral vector-based vaccines (whole or
parts of tumor antigens)
 DC vaccines (peptide-pulsed or tumor
lysate pulsed
Antigen non-specific vaccines:
 Allovectin (viral induced allo MHC
expression in tumors)
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1.3. Adoptive T-cell Therapy
Interleukin-2 (IL-2) was FDA approved for the treatment of late-stage
melanoma in 1998 (20, 21). The treatment of late-stage melanoma patients consisted
of intravenously (I.V.) giving patients high dose infusion (600,000-720,000 IU/kg)
IL-2 every 8 hours, with several rounds of these high dose-IL-2 infusions given 3-5
weeks apart (20, 21). Using high-dose IL-2 to treat melanoma patients has resulted in
varied response rates. In patients containing one or more visceral lesions, this highdose IL-2 resulted in clinical response rates of only 10-15%, while patients that
contained cutaneous melanoma response rates reached 50% objective response rates
(20, 21). In patients with visceral metastasis, treatment with high-dose IL-2 resulted
in 5-6% of patients undergoing complete remission that has lasted over 10 years (20,
21).
Results from using high-dose IL-2 to treat melanoma patients prompted
researchers at the National Cancer Institute (NCI), Bethesda, Maryland to investigate
the role of combining high-dose IL-2 with adoptive T-cell therapy (ACT) (12, 22).
ACT is a type of passive immunotherapy that acquires either cancer patient peripheral
blood or lymphocytes obtained within a tumor and expands these cells into large
numbers using growth factors (such as IL-2) in a laboratory (17, 18, 23). These cells
are then re-infused into the patient. In the following section, I will discuss the
different types of adoptive T-cell therapy, which vary in the site where the
lymphocytes are collected and the methods used to expand the cells (Figure 1.3). A
major advantage of using ACT to treat cancer patients is the opportunity for
researchers to select or engineer in vitro the desired or optimal T-cell phenotype,
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function, anti-tumor response, antigen specificity, and expand this selected population
prior to infusing the cells back into the patients.
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Figure 1.3.Different forms of adoptive T-cell therapy. A schematic representation
of the process of large expansion of TILs derived from tumor fragments or circulating
antigen-specific T cells from peripheral blood for adoptive T cell therapy.
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Figure 1.3. Different forms of adoptive T-cell therapy.
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1.3 a) Tumor-Infiltrating Lymphocytes
When ACT was first combined with high-dose IL-2 at the NCI by Grimm and
colleagues in 1982, they developed a novel cytolytic cell system using lymphokine
activated killer (LAK) cells (22, 24, 25). LAK cells were generated from cancer
patient peripheral blood lymphocytes and normal donors, using high-dose IL-2 to
grow the cells (22, 24, 25). Using animal models, infusion of LAK cells and highdose IL-2 was able to eradiate metastatic tumors (22, 24-27). In 1985, Rosenberg and
colleagues demonstrated in a clinical trial that LAK cells infused with high-dose IL-2
had an impact on metastatic melanoma patients resulting in a 21% response rate (2628). In a follow-up study conducted in 1987, it was demonstrated that combining
high-dose IL-2 with LAK cells was more effective in treating cancer patients than
high-dose IL-2 alone (26-28). However, in the clinical trial conducted by Rosenberg
and colleagues, the majority of the responses were partial responses and this initiated
the investigators to inquire about other cells that may induce anti-tumor responses.
It was demonstrated in 1986, using mice models, that tumor-infiltrating
lymphocytes (TIL) obtained from melanoma tumors from the mouse could be
expanded in vitro in IL-2 and subsequently eradicate the tumors when adoptively
transferred (11, 29, 30). In a phase II trial, when metastatic melanoma patients were
treated with TIL and high-dose IL-2, the response rate was 39% (11, 29). However,
in a groundbreaking Phase II clinical trial in 2002 , conducted at the NCI, Dudley and
colleagues demonstrated that combining cyclophosphamide and fludarabine (a
lymphodepleting chemotherapy regimen) prior to infusing the TIL with high-dose IL2 resulted in 50% response rates in metastatic melanoma patients (17, 31, 32).
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Lymphodepletion allowed the transferred TIL to persist better in the patient and rid
any cells that may be in competition with the infused TIL for homeostatic cytokines,
such as Interleukin-7 (IL-7) and Interleukin-15 (IL-15) (17, 31-34). In addition,
lymphodepletion also eliminates endogenous suppressor cells such as T regulatory
cells (Tregs) that may inhibit the infused T cells functions (31-36). However, the reappearance of Tregs and other suppressor cells and factors that may inhibit T-cell
function is a concern even after lymphodepletion (31-34) (35, 36). Therefore, new
approaches using total body irradiation (TBI) of 2Gy or 12Gy, in addition to the
traditional cyclophosphamide and fludarabine lymphodepletion have been developed
at the NCI (17, 37). Using the 12Gy TBI plus chemotherapy, the NCI found an
impressive objective clinical response rate of 72% and a complete response rate of
40% (17, 37).
The standard protocol for ACT using TIL for the treatment of metastatic
melanoma patients is as follows (Figure 1.4). The melanoma tumor is surgically
resected from the patient. The tumor is then subsequently cut up into multiple 35mm2 fragments or enzymatically digested using collagenase and hyaluronidase and
Ficoll to isolate the TIL and placed in a 24-well plate with TIL-media and high-dose
IL-2 (6,000IU/ml) for a period of 4-5 weeks (17, 23, 38). After this period, the TIL
are referred as ‘pre-Rapid Expansion’ TIL or pre-REP TIL. The pre-REP TIL are then
subjected to undergo the REP. The REP is a 2 week expansion period in which the
TIL are placed in flasks with TIL-media, high-dose IL-2, anti-CD3, and irradiated
peripheral blood mononuclear cells (PBMCs) that we refer to as feeder cells (18, 23,
39). After the 2 week expansion period, the TIL are referred to as ‘post-REP’ TIL.
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During the expansion period, the TIL numerically expand to billions of cells (18, 23,
39). The billions of post-REP TIL are then infused into a lymphodepleted patient and
high-dose IL-2 is subsequently given in order to help the transferred TIL persist (18,
23, 39). Using this TIL to treat metastatic melanoma patients has resulted in clinical
response rates of 50% in Phase II clinical trials at NCI, as well as other centers
around the world, including at MD Anderson Cancer Center (18, 38, 40). Although
TIL therapy was pioneered and has been mainly studied in melanoma, TIL therapy
has also been developed to treat patients with breast cancer, renal cancer, ovarian
cancer, lung cancer, cervical cancer, gastric cancer, and head and neck cancers.
An advantage of using TIL therapy to treat metastatic melanoma patients is
that TIL have a polyclonal nature that recognize multiple tumor-associate antigens
(TAA), including melanocyte/melanoma differentiation antigens as well as a wide
range of unknown antigens. However, alternative approaches have been developed to
expand antigen specific T cells from patient-derived PBMCs.
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Figure 1.4. Schematic representation of the process of TIL expansion and TIL
therapy for metastatic melanoma starting from tumor fragments. Suitable tumors
from eligible stage IIIc-IV patients are resected and taken to the lab under sterile
conditions where they are cut up into small 3–5 mm2 fragments and placed in culture
plates or small culture flasks with growth medium and high-dose (HD) IL-2. The TIL
are initially expanded for 3–5 weeks during this “pre-rapid expansion protocol” (preREP) phase to at least 50 × 106 cells. The cells are then subjected to a rapid expansion
protocol (REP) over two weeks by stimulating the T cells using anti-CD3 in the
presence of PBMC feeders cells and IL-2. The expanded TIL (now billions of cells)
are washed, pooled, and infused into the patient followed by one or two cycles of HD
IL-2 therapy. Before TIL transfer, the patient is treated with a preparative regimen
using cyclophosphamide (Cy) and fludarabine (Flu) that transiently depletes host
lymphocytes “making room” for the infused TIL and removing cytokine sinks and
regulatory T cells in order to facilitate TIL persistence.
Reprinted with permission from: Wu R, Forget MA, Chacon J, Bernatchez C,
Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Cancer J. 2012 Mar-Apr;18(2):160-75.
doi: 10.1097/PPO.0b013e31824d4465.
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Figure 1.4. Schematic representation of the process of TIL expansion and TIL
therapy for metastatic melanoma starting from tumor fragments.
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1.3 b) Chimeric Antigen Receptor
Another exciting form of ACT utilizes chimeric antigen receptors (CAR). The
first generation of the CAR contained a link between light chain and heavy chain of a
monoclonal antibody with variable domains (41, 42). This was associated with
transmembrane and the T-Cell Receptor (TCR) complex cytoplasmic tail of the zeta
(ζ) chain (41, 42). Engineering T cells using this approach was developed to
circumvent Major Histocompatibility Complex (MHC) restriction due to the fact that
tumor cells evade recognition by down-regulating the MHC. However, this first
generation of the CAR led to poor proliferation of the engineered T cells and it was
noted that stimulation of the TCR via the cytoplasmic tail of the zeta (ζ) chain was
insufficient to help the T cells persist (41, 42). Therefore, the second generation of the
CAR was generated to provide improved co-stimulation to the T cells by adding the
CD28 endo-domain, in addition to the zeta (ζ) chain that was already on the first
generation CAR in order to mimic the two-signals needed for T-cell activation (43,
44). Other endo-domains from other co-stimulatory molecules have been added to the
CAR constructs, such as the endo-domains from CD137 (4-1BB and CD134 (OX40)
to generate a third generation of CAR consisting of the zeta (ζ) chain, and the endodomains of CD28 and CD137 (45).
Adoptive transfer of autologous CAR transduced T cells induced substantial
tumor regressions in leukemia and B-cell lymphomas (46, 47). While treating
leukemia and B-cell lymphomas, CAR constructs contained a CD19-specific
Immunoglobulin G (IgG) single chain variable fusion (scFv) fused to the TCR ζ chain
and the endo-domains of CD137 (46, 47). Treatment of leukemias and lymphomas
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using CAR transduced T cells have shown promising results in regards to anti-tumor
activity and persistence (46, 47). In regards to melanoma treatment, targets of CAR
transduced T cells include overexpressed genes, such as gangliosides GD2, and GD3,
which are over expressed in 50-80% of metastatic melanomas (48, 49). Using IL-2
administration and a second generation CAR that targeted GD2 with endo-domains of
CD28 and CD134 significantly improved the survival of mice following transfer (50).
In addition, researchers found that administering IL-2 and using a TCR transduced
car that targeted GD3 and contained CD28 endo-domain resulted in complete
response rate in 50% of melanoma tumor-burdened mice (49).
1.3 c) TCR-transgenic T cells
Another type of ACT involves TCR-transduced T cells. These T cells are
transduced using retroviral or lentiviral vectors containing TCR genes that encode
variable regions for different melanoma-associated antigens, such as glycoprotein100 (gp100) and melanoma antigen recognized by T cells-1 (MART-1) (51, 52).
In a pilot trial, T cells were transduced with a gp-100 specific TCR and
infused with IL-2 into melanoma patients that had been previously lymphodepleted
(53, 54). The TCR-transduced T cells persisted and no toxicity was detected in the
patients, however, the T cells demonstrated minimal effector function due to the low
surface levels of the gp-100 TCR (53, 54). However, when high-affinity MART-1
transduced TCR T cells were expanded and infused into melanoma patients, this
resulted in a 30% clinical response rate (55, 56). CD4+ T cells have also been
transduced to target another melanoma antigen, NY-ESO-1, and have demonstrated
objective response rates in 5 out of 11 patients, with 2 complete responses (57).
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1.3 d) Antigen-specific CD8+ and CD4+ T cells.
Using autologous patient PBMCs, tumor-associated antigen (TAA)-specific
CD4+ and CD8+ T cell clones have been expanded using multiple in vitro antigen
stimulations. CD8+ T cells are believed to be the optimal population for ACT due to
their specialized ability to recognize and kill tumors via the TCR binding to the
peptide:Major Histocompatibility Complex (MHC) class I (58). Using ACT, various
groups have attempted to use antigen-specific CD8+ cells to treat metastatic
melanoma patients (58, 59). A key approach isolates lymphocytes from peripheral
blood of patients. CD8+ T cells that recognize melanoma antigens gp100, MART-1 or
tyrosinase are expanded using autologous mature dendritic cells that have been pulsed
with peptide (59-62). In a phase I clinical trial, CD8+ T-cell clones that recognized
MART-1 and gp100 that were expanded and infused into metastatic melanoma
patients were able to respond to IL-2, persist in vivo, traffic to the tumor sites and
induce tumor regression (59, 63, 64). Using this approach resulted in clinical
responses of about 30%, with patients experiencing complete responses, partial
responses, or stabilization of the disease for up to 11 months (59, 63, 64). In another
clinical trial conducted by Mackensen and colleagues, a 30% clinical response was
demonstrated when melanoma patients received MART-1-specific T cells that were
able to migrate to the tumor sites (59, 62). Butler et al. conducted studies using K562
artificial antigen presenting cells (aAPCs) to expand MART-1 specific CD8+ T cells
(65). The aAPCs were transduced to express MART-1, HLA-A2, CD86 and 4-1BBL
and the MART-1 specific CD8+ cells were obtained from melanoma patient
peripheral blood (65).
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Currently, the specific role of antigen-specific CD4+ used to treat metastatic
melanoma patients is being investigated (66). Studies have demonstrated that
adoptively transferring tumor reactive CD4+ T helper (Th)17 cells into C57Bl/6 mice
resulted in tumor eradication (67, 68). Although the use of antigen-specific CD8+ T
cells have been largely studied, many groups believe that polyclonal CD4+ and CD8+
population used for ACT for melanoma patient treatment may be necessary to induce
better clinical responses (61, 69-71). In addition to the HLA class I-restricted
melanoma antigens mentioned earlier, there are also HLA class II-restricted
melanoma antigens, such as tyrosinase, NY-ESO-1 and Melanoma Associate antigen1 (MAGE-1) (60). A clinical trial using Th1 CD4+ T cells clones that were specific
for tyrosinase or NY-ESO-1 antigens to treat melanoma patients demonstrated a
persistence of these cells for up to 2 months (60). In addition, four patients showed a
partial response or stabilization of the disease and one patient exhibited complete
durable response of more than 3 years (60).
1.4) Drawbacks of ACT using TIL
1.4 a) T-cell differentiation
The differentiation stage of the T cells that are infused and subsequently
associated with clinical responses has been investigated. The stages of differentiation
for majority of CD8+ TIL used in ACT for metastatic melanoma treatment are T
effector-memory, (TEM), effector (TEFF), and terminally differentiated effector cells
(TTDE) (72, 73). The more differentiated the cells, the more cytolytic they will
become, but they will have a lower proliferative capacity (72, 73). Also, more
differentiated cells tend to lose critical co-stimulatory molecules such as CD27 and
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CD28 (72-75). The markers for the different stages of differentiation are
demonstrated in (Figure 1.5). A small percentage of TIL have been found to be
central memory T cells (TCM). When TIL are expanded with high-dose IL-2, this can
induce differentiation of the T cells (76). TCM are able to traffic to the lymph nodes
in vivo where they may encounter antigen-presenting cells that present TAA (77, 78).
Studies have demonstrated using mice models that antigen-specific TCM persisted
long-term in vivo, while inducing an anti-tumor response (73, 77, 78). However, some
of these findings were observed when a cancer vaccine with a specific TAA was
administered following adoptive transfer of the TCM, and it has not been determined
whether TCM are the optimal population for ACT in the absence of a cancer vaccine
(73, 77, 78).
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Figure 1.5. Stages of CD8+ T-cell differentiation found in melanoma CD8+ T-cell
in TIL and phenotypic markers assessed by flow cytometry used to delineate
these stages. CD8+ T cells in TIL can be found having markers of central
memory (TCM), effector memory (TEM), effector (TEFF) or terminallydifferentiated effector (TTDE) stages. These stages and markers are based on
previous work on anti-viral CD8+ T-cell response and the states of CTL
differentiation associated with the control of both acute and chronic viral infections in
humans. These markers are only a guide to identify these functional memory or
effector stages and may not always fit into these defined categories. In addition, the
expression of these subset markers may be transiently down-modulated, permanently
lost, or re-expressed under different cytokine or in different tissue niches in vivo.
Nevertheless, understanding the changes in these effector and memory markers in
TIL is very useful in biomarker studies to identify clinically active T-cell subsets.
Melanoma TIL expanded for therapy are a mixture of mostly TEM, TEFF, TTDE (that
have lost CD28 expression). Relatively very few TCM are found (<5%). Initially, NK
cells are found in initial TIL expansions (pre-REP), but these are lost after the REP
which selectively activates the T cells.
Reprinted with permission from: Wu R, Forget MA, Chacon, J, Bernatchez C,
Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Cancer J. 2012 Mar-Apr;18(2):160-75.
doi: 10.1097/PPO.0b013e31824d4465.

- 25 -

Figure 1.5. Stages of CD8+ T-cell differentiation found in melanoma CD8+ T-cell
in TIL and phenotypic markers assessed by flow cytometry used to delineate
these stages. CD8+ T cells in TIL can be found having markers of central
memory (TCM), effector memory (TEM), effector (TEFF) or terminallydifferentiated effector (TTDE) stages.
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1.4 b) Long process of Isolating TIL for Adoptive T-cell Therapy
Although ACT using TIL has resulted in a 50% clinical response rate across
various institutes (17, 23, 38, 40), one of the caveats for this therapy is the actual
expansion of the TIL. The process of isolating and expanding TIL from melanoma
tumors can be time-consuming and labor intensive. In addition, not all TIL from all
patients are able to be isolated and expand (17, 23, 38, 40). In order for the TIL to be
eligible for the secondary expansion (REP), the pre-REP TIL must reach a minimum
of 50x106 cells following the initial isolation and expansion period (23, 38). However,
only 65% of patients pre-REP TIL reach this threshold (23, 38). Although the
expansion period induces the growth of billions of TIL, this process may also induce
differentiation (23, 38). An approach to shorten the time expanding the TIL without
inducing the differentiation of the TIL is referred to as the ‘young’ TIL method. This
approach uses enzymatic digestion, not the traditional fragment set-up to isolate the
TIL from the tumor (40, 79-82). The TIL are then expanded with high-dose IL-2 over
a period of 3-5 weeks. Using the enzymatic digest method to expand the TIL has
shown success in generating the minimum number of pre-REP TIL needed to undergo
the secondary expansion in as little as 3 weeks, increasing the number of patients
eligible for secondary from 50-60% to 80% (79-82). In addition the ‘young’ TIL
protocol does not test for anti-tumor reactivity in the TIL, therefore all patient TIL
undergo the secondary expansion despite their anti-tumor reactivity and are infused
into lymphodepleted patients, along with high dose IL-2. Besser and colleagues
reported the results of their first clinical trial that utilized the ‘young’ TIL protocol
(79, 83). They reported a clinical response of 50%, which was comparable to the
response rates seen with using the conventional method to isolate and expand the TIL
- 27 -

(79, 83). Although the ‘young’ TIL method did not increase the clinical response
rates, it can be alluded that the ‘young’ TIL are less differentiated and may persist in
vivo longer, and overall, this method reduces the initial isolation expansion period.
1.5) Co-stimulation
When a T-cell becomes activated, it requires 2 initial signals. Signal 1 occurs
when the T-cell receptor (TCR) binds to the MHC: peptide complex on an antigen
presenting cell (APC) (84, 85). The first signal initiates the activation of the T-cell.
The second signal occurs when CD28 on the T-cell interacts with CD80/86 on an
APC (84, 85). The second signal involves co-stimulation and helps the T-cell persist.
If T cells receive these 2 signals they will undergo proliferation, differentiation, and
then acquire effector functions (84, 85). A third signal involves cytokines released
from the APC that may influence the differentiation and proliferation of the T-cell.
However, after these initial activation events occur, additional co-stimulatory
receptors/ligands are up-regulated on both T cells and APCs. These additional costimulatory molecules are members of the Tumor Necrosis Factor Receptor (TNFR)
super family, 4-1BB (CD137) and/or OX40 (CD134) (84, 85). In conjunction with
the TCR-CD3 complex and CD28 signaling, the ligation of 4-1BB on T cells using an
agonistic anti-4-1BB monoclonal antibody (mAb) can present an additional signal
(86-88).
These co-stimulatory molecules are important to initiate T-cell survival and
proliferation. Co-stimulatory signals may perform several functions, such as
augmenting production of IL-2, inducing cytokine production, suppressing cell death
by altering bcl-2 and caspase protein function and enhancing memory T cell
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development (87-92). In the absence of co-stimulation, a T-cell can become
susceptible to become anergic. Co-stimulatory molecules play crucial roles in all
phases of T-cell response, not only in the activation phase but also in the effector
phase, expansion phase, and memory phase (87-92).
1.5 a) 4-1BB discovery and its signaling pathways
4-1BB was discovered using a screening method to identify new genes in
mice that were induced after T-cell activation (93-95). In humans, 4-1BB was initially
termed ‘induced by lymphocyte activation (ILA) (93-95) and is 60% homologous to
the mouse 4-1BB (93-96). 4-1BB is an activation dependent gene that is a 30-kDa
monomer and 55-kDa homodimer (91, 93-96). The mouse 4-1BB gene consists of 10
exons, 8 exons in the coding region and 2 in the 5’ untranslated region (91, 93-96).
The human 4-1BB gene encompasses 255 amino acids and was initially cloned from
the activated human T-cell leukemia virus type-1 (HTLV-1) transformed human T
cell library (91, 93-96).
The ligand for 4-1BB is 4-1BB ligand (4-1BBL) (91, 96-98). In 1994,
Alderson and colleagues were the first to isolate the human 4-1BBL gene using a
fusion protein that contained the extracellular region of 4-1BB couple to IgG1 Fc
region (98). 4-1BBL is a Type II transmembrane protein and is primarily expressed
on antigen presenting cells (APCs) (96, 98).
4-1BB encodes Type-I surface glycoproteins that consist of extracellular
domain, transmembrane region, and intracellular region (91, 99). The intracellular
regions of 4-1BB associate with TNFR-associated factor-2 (TRAF 2) and p56lck (91,
99). Upon 4-1BB receptor binding to its ligand, 4-1BBL, the cytoplasmic tail of 4-
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1BB contains TRAF-binding regions that then recruit TRAFs (91, 99). The TRAF
molecules associated with 4-1BB signaling are TRAF1, TRAF2, and TRAF3 (in
humans) (Figure 1.6) (85, 91, 99). The TRAF trimers (1, 2, and 3) are recruited to
TRAF-binding motifs in cytoplasmic tail of 4-1BB upon activation (85, 91, 99).
These TRAFs form heterotrimers upon receptor-ligand association (85, 91, 99). After
T-cell activation, TRAF1 is up-regulated. Since TRAF1 lacks the RING finger
domain needed to induce NFκB activation, TRAF1 mainly acts as a modulator for
TRAF2, protecting TRAF2 from undergoing degradation after 4-1BB ligation and
signaling (85, 91, 99). TRAF2 employ E3 ubiquitin ligase activity and link 4-1BB to
the downstream signaling pathways (85, 87, 100, 101). If T cells are defective or lack
TRAF2, cytokine production and p38 activation will be negatively affected in
response to 4-1BB activation (85, 87, 100, 101).
The 4-1BB 5’ promoter region contains binding sites for NFκB and AP-1,
which are involved in TCR activation-dependent transcriptional regulation of 4-1BB
promoter (85, 87, 100-102). The expression of 4-1BB is up-regulated through MEK
and C-Jun-N-terminal kinase-1 (JNK) activity (85, 87, 100, 101). 4-1BB signaling
through the NFκB, phosphoinositide 3-kinase (PI3K) pathways regulate cytokine
production, cell proliferation, memory development, and anti-apoptosis molecules,
such as bcl-2 and bcl-xL (Figure 1.6).
1.5 b) The role of 4-1BB in Immunotherapy
4-1BB expression is up-regulated after activation. 4-1BB is expressed on T
cells, B cells, Natural Killer (NK) cells, neutrophils, monocytes, and dendritic cells
(DCs) (85, 89, 103). The expression of surface 4-1BB reaches maximal levels
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between 24-48 hours (85, 89, 103). Ligation of 4-1BB receptor with 4-1BBL induces
anti-apoptotic signals, proliferation and cytokine production via NFκB, p38 and PI3K
pathways (85, 89, 103). 4-1BB activation also prompts the proliferation and
expansion of CD8+ T cells, resulting in their production of IL-2, IFN-gamma, and
Tumor Necrosis Factor (TNF)-alpha that initiates an anti-tumor response (85, 89,
103). In antigen specific T cells, the expression of 4-1BB is rapid and diverse in
CD4+ versus CD8+ T cells (85, 89, 103). An increase in 4-1BB expression was not
seen in T cells until 12 hours after activation, where CD8+ T cells expressed higher
levels of 4-1BB than CD4+ T cells (85, 89, 103). 4-1BB expression in CD8+ and
CD4+ T cells was decreased to baseline by 48 hours (104, 105). Many researchers
speculate that CD4+ T cells may be less responsive to 4-1BB ligation than CD8+ T
cells and this could explain the preferential expansion and effect on CD8+ T cells
upon 4-1BB activation (104, 105). 4-1BB ligation induces a profound effect on CD8+
T cells (104, 105). Researchers have found that 4-1BB activation can inactivate CD4+
T-cell effector functions or even kill CD4+ cells (104, 105).
As mentioned earlier, 4-1BB activation leads to increased CD8+ proliferation
and effector functions. Investigating the anti-viral effects in a 4-1BB-/- mice
demonstrated that the 4-1BB-/- mice have normal primary CD8+ responses, but exhibit
a decrease in secondary responses (106). These findings suggest that 4-1BB
activation may be critical for late anti-viral responses (85, 106).
When the anti-tumor effect was compared in a 4-1BB+/+ and 4-1BB-/- mice
using the B16.F10 melanoma cell line to challenge the mice, there was increased
mortality in the 4-1BB-/- mice compared to the 4-1BB+/+ mice (96, 97). This anti-
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tumor effect was due to the increased survival of the CD8+ T cells, and increased
IFN-gamma production in the 4-1BB+/+ mice (96, 97).
4-1BB ligation by cell surface 4-1BBL or using agonistic anti-4-1BB
antibodies initiates a co-stimulatory signal to cells and enhances T-cell survival via
increased anti-apoptotic molecules (96, 97). Melero and colleagues were the first to
demonstrate that treating tumor-bearing mice using an agonistic anti-4-1BB antibody
eradicated the tumors in the mice (107). However, when Sabel et al. co-injected
tumor cells with PBMCs in a severe combined immunodeficiency (SCID) mouse and
administered an anti-human anti-4-1BB antibody, there was no lymphocyte-mediated
tumor eradication or suppression, and the tumors continued to grow (108). The
authors speculated that this may have been a result of the adoptively transferred
PBMCs being killed by endogenous NK cells in an antibody-dependent cellular
cytotoxicity (ADCC) manner (108). Bertram et al. illustrated that in 4-1BBL-/- mice,
there was decreased antigen specific (Db/NP366-374) CD8+ T cells responses (85,
109).
Miller and colleagues demonstrated that treating tumor challenged mice with
an anti-4-1BB antibody was only effective once the tumor was already established
(92). Their study indicated that the anti-4-1BB antibody acted on T cells that were
already antigen-experienced (92). The effect of an anti-4-1BB antibody was also
determined in a lung metastases model. When T cells and anti-4-1BB antibody were
administered to mice bearing lung metastases, the mice exhibited tumor regression,
compared to when T cells alone were administered (88).
1.5 c) 4-1BB signaling outside of the T-cell realm
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4-1BB is expressed on a variety of cells (T cells, B cells, NK cells, and DCs),
thus the effects of an anti-4-1BB antibody can mediate effects in these cells as well.
Activation of monocytes using an agonistic anti-4-1BB antibody exhibited an
increase in the production of IL-8 and TNF-alpha, but a decreased production of IL10 (110). Zhang et al. demonstrated that when PBMCs were activated using
pokeweed mitogen, human B cells expressed 4-1BB (110, 111). The expression of 41BB on B cells was also up-regulated using an anti-CD40/anti-Ig in combination with
IFN-gamma (110, 111). In addition, when B cells were incubated with the P815
mastocytoma cell line that had been transfected with 4-1BBL, the B cells’ survival
and proliferation was enhanced (110, 111). In addition, the B cells increased TNFalpha and TNF-beta, indicating that the expression of 4-1BB on B cells was
functional (110, 111). 4-1BB has been demonstrated to be expressed on activated NK
cells, but not on resting NK cells (110). 4-1BB activation using an agonistic anti-41BB antibody did not affect the NK cell cytolytic function or anti-tumor function
during tumor progression (110).
4-1BB is expressed on DCs and signaling via CD40 can down-regulate the 41BB expression (110, 112-114). Wilcox demonstrated that in vivo administration of
an agonistic anti-4-1BB antibody to naïve mice increased the ability of DCs to
activate T cell and induce their proliferation (110, 112-114).
1.5 d) 4-1BB monoclonal antibodies in the clinic
4-1BB is transiently expressed on CD4+ and CD8+ T cells, although it is
preferentially expressed more on CD8+ T cells. 4-1BB expression is increased after
TCR activation and its expression can be seen for up to 4-5 days after TCR activation
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(105). Agonists to 4-1BB and/or 4-1BBL have been found to induce an increase in
cytolytic T lymphocyte (CTL) activation, Interferon-gamma (IFN-gamma) secretion
and initiate an anti-tumor and anti-viral response (86, 91, 96, 99). In addition, 4-1BB
has recently been indicated as a potential biomarker for tumor-specific T cells (115).
Due to the numerous studies demonstrating 4-1BB as a powerful co-stimulatory
molecule for the expansion and effector function of CD8+ T cells (86, 90, 104),
agonists to 4-1BB have been developed to use in the clinic.
Bristol Myers Squibb (BMS) developed a fully-human agonistic anti-4-1BB
antibody (BMS-663513 or Urelumumab) that demonstrated anti-tumor effects in a
Phase I clinical trial in patients with melanoma renal cell carcinoma, and ovarian
cancer (89, 116).There was tolerable side effects in the phase I trial, so this led to the
development of phase II trials in melanoma patients, in which the anti-4-1BB
antibody was used alone for treatment or in combination with chemotherapy or
radiation (89, 116). However, when higher doses of the anti-4-1BB antibody were
used, there was a considerable amount of liver toxicity observed (89, 116). Although
the reason behind the liver toxicity was not determined, it is speculated that NK cells
present in the liver, were non-specifically activated (89, 116).
In a mouse study, it was observed that when high concentrations or repeated
doses of anti-4-1BB agonistic antibody were injected into naïve or irradiated mice,
the mice exhibited adverse side effects, such as induction of lymphopenia and
decreased lymphokine trafficking (87, 89, 99). The antibody also induced an intense
accumulation of T cells in the liver (87, 89, 99). This detrimental finding may be
explained by a number of other reasons. The surface expression of 4-1BB, as well as
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the recruitment of the TRAF members, depends on the activation state of the cells (87,
89, 99). This needs to be taken into consideration when administering the anti-4-1BB
antibody systemically.
Pfizer developed an agonistic antibody against 4-1BB (PF-05082566, GTC
Biotherapeutics) and has started clinical testing and is currently being tested in
synergy with rituximab for the treatment of lymphoma patients (117).
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Figure 1.6. 4-1BB signaling pathways. When 4-1BB is activated by 4-1BBL or
agonistic antibodies, it triggers the TRAF heterodimers to form and initiates
downstream signaling.4-1BB signaling induces the proliferation and survival of cells
via PI3K, NFκB, and up-regulation of bcl-2 and bcl-xL.
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Figure 1.6. 4-1BB signaling pathways.
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1.6 Main theoretical questions posed in this dissertation
Although activating the 4-1BB pathway using agonistic anti-4-1BB antibodies
exhibit an increase in cytotoxic T lymphocyte (CTL) activity in tumor and viral
models, there was liver toxicity observed in melanoma patients in phase II clinical
trials. Therefore, we have investigated ways to utilize the anti-4-1BB antibody in
improving adoptive T-cell therapy used to treat melanoma, without the possibility of
inducing adverse side effects, such as non-specific activation of other cells. We have
previously found that post-REP TIL are susceptible to activation-induced cell death
(AICD). However, we observed that using agonistic anti-4-1BB antibodies protected
the post-REP TIL from AICD. This initial observation prompted us to further
investigate the role of activating the 4-1BB during the expansion of the TIL. In our
study, our overall goal was to try to improve the overall quality of the TIL used for
Adoptive T-cell therapy. Although ACT using TIL has resulted in 50% response rates,
we believe there are innovative ways to try and improve this therapy during the
different stages of generating the tumor-infiltrating lymphocytes. In this study, we
activate the 4-1BB pathway by utilizing an anti-4-1BB antibody during the expansion
of the TIL. We wanted to investigate whether activating the 4-1BB pathway would
induce an optimal T-cell product that would generate anti-tumor functions and persist
in vivo. In addition, if providing co-stimulation to the TIL during the initial expansion
period using the anti-4-1BB antibody, we wanted to further investigate the possible
mechanism by which this could be occurring.

- 38 -

1.7 Overall hypothesis and Specific Aims
Our overall hypothesis is that providing additional co-stimulation to the TIL
through the 4-1BB signaling pathway can improve the TIL phenotype, effector
function, and in vivo persistence, providing an overall better TIL product for
melanoma adoptive T-cell therapy. In this dissertation, we tested our hypothesis
under the following specific Aims:
AIM I: Determine whether activation of the 4-1BB pathway during the initial
TIL isolation and expansion affects melanoma TIL proliferation and phenotype.
AIM II: Determine whether 4-1BB ligation augments the signaling pathways
in the T cells during the initial TIL isolation.
AIM III: Determine whether activation of the 4-1BB pathway affects
melanoma TIL phenotype, cytolytic activity and persistence during secondary
expansion.
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CHAPTER 2
Early activation of the TNFR super family member 4-1BB pathway
for the expansion of tumor-infiltrating lymphocytes for Adoptive Tcell Therapy for metastatic melanoma patients
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2.1 Rationale and Hypothesis
My first Aim seeks to extend the number of metastatic melanoma patients who can
benefit from Adoptive T-cell therapy (ACT) and improve the efficacy of the
treatment. ACT using tumor-infiltrating lymphocytes (TIL) has emerged as a
powerful therapy for patients that have failed first and second line therapies. T-cellbased therapies have emerged to be powerful mediators of anti-tumor responses in
both hematologic and solid tumors (11, 17). Over the past 3 decades, accumulating
evidence has demonstrated the potential of treating metastatic melanoma patients with
their own tumor-infiltrating lymphocytes (TILs) as a form of personalized therapy (11,
17, 38). TIL therapy for melanoma is predicated on the enriched tumor antigenspecificity of T cells infiltrating tumors which can be expanded to high numbers and
re-infused. The protocol used in most centers involves the initial outgrowth of TILs
from 3-5 mm2 cut fragments from metastatic melanoma surgical resections or
biopsies using IL-2 as growth factor (11, 17, 38). These initial tumor fragment
cultures usually take about 3-5 weeks to yield enough TIL for secondary expansion in
larger scale to yield the final infusion product. Although earlier clinical trials were not
that encouraging, the introduction of a non-myeloablative transient lymphodepleting
chemotherapy regimen before adaptive transfer of autologous TILs expanded ex vivo
has significantly boosted clinical response rates to around 45-50% (29, 30). Phase II
clinical trials in a number of TIL therapy centers around the world using this general
approach of tumor fragment-derived TIL has reproduced these results and long-term
follow-up of patients treated with their own TIL is now also showing a survival
benefit over other conventional therapies, especially in patients that have progressed
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even after other immunotherapies such as IL-2, anti-CTLA-4, and anti-PD-1(11, 17,
38, 79).
CD8+ TILs enriched in tumor specificity have emerged to be critical in
mediating tumor regression in a number of Phase II TIL trials, and current efforts are
now aimed to not only increase the expansion of CD8+ T cells from tumor tissue, but
also increase the anti-tumor activity and effector-memory phenotype of the final TIL
infusion product to improve persistence after adoptive transfer (17, 18, 38, 58, 79,
118). In addition, accelerating the rate of TIL expansion from the initial tumor
fragment cultures has also become a priority to minimize the time the cells are in
culture and shorten the time from surgery to treatment and prevent patient protocol
withdrawal, especially when contemplating out-scaling TIL manufacturing to larger
cohorts of patients (79, 80, 82, 119). Metastatic melanomas contain a population of
CD8+ T cells expressing activation markers, such as PD-1 and 4-1BB/CD137,
indicating a recent history of antigenic stimulation in the tumor microenvironment in
vivo (115). Recent studies have found that CD8+ TIL expressing 4-1BB especially
represent the most highly enriched tumor-specific sub-population of T cells in
melanoma (115). Protocols are now being developed to purify 4-1BB+ CD8+ T cells
from melanoma tissues and expand these selected cells for infusion. Although this
approach is promising, it has a number of caveats, including the need to prepare
single cell suspensions from tumor tissues, the variable and sometimes low frequency
of 4-1BB+ T cells in tumors that can make positive selection methods difficult, the
small sizes of tumor tissue available in many cases from biopsies of surgical
resections that yield few cells after enzymatic digestion or mechanical disaggregation,
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and the possibility that not all tumor-specific CD8+ T cells may be in an activated (41BB+) state at the time the tumor was taken out and processed for TIL expansion.
An alternative approach that may overcome these issues, and also opens up
more translational possibilities, is to directly manipulate co-stimulatory pathways
within the initial melanoma tumor fragment cultures themselves to capitalize on the
de novo expression of co-stimulatory molecules due to previous antigenic stimulation
on resident CD8+ T cells which can accelerate the rate of TIL expansion out of the
tumor fragments and may also enrich the tumor-specific T cells at the same time. In
addition, additional antigenic stimulation may occur during the early tumor fragment
culture from antigen presentation that may induce further T-cell co-stimulatory
molecule expression that can be further used to further enhance T-cell outgrowth.
Tumor fragments have been used for years to expand TIL by simply adding
exogenous IL-2, but whether other immunomodulators can be added in these tumor
fragment cultures to affect TIL expansion and phenotype has basically been ignored.
In this study, we surmised that the 4-1BB co-stimulatory pathway could be
exploited in these initial melanoma tumor fragment cultures in an active rather than a
passive way and hypothesized that activating 4-1BB signaling using agonistic anti-41BB antibodies would enhance the output of CD8+ T cells, their tumor reactivity, and
memory properties. We found that 4-1BB expression is commonly seen on resident
CD8+ T cells in melanoma metastases and is maintained during the culture of tumor
fragments for at least a week in a significant frequency of CD8+ T cells in these early
cultures ex vivo. We tested the effects of an agonistic anti-4-1BB antibody added
during the initiation of individual tumor fragment cultures and found that this
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increased the rate of CD8+ TIL expansion as well as the tumor reactivity of the
expanded product.
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2.2 Results
4-1BB is expressed on freshly isolated melanoma tumor-infiltrating lymphocytes.
We wanted to investigate what co-stimulatory molecules were expressed on freshly
isolated melanoma TIL. We wanted to determine whether 4-1BB and OX40 costimulatory molecules were expressed on freshly isolated TIL from melanoma tumors.
Melanoma tumors were surgically resected from metastatic melanoma patients and
single cell suspensions were prepared and stained for CD4, CD8, 4-1BB and OX40.
In 18 independent TIL samples, we found that 4-1BB was mainly expressed on CD8+
TIL (Figure 2.1A), whereas OX40 was mainly expressed on CD4+ TIL (Figure
2.1B).
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Figure 2.1. Detection of 4-1BB and OX40 on freshly-isolated CD8+ TIL. Using
flow cytometry, we measured the expression of 4-1BB and OX40 on CD8+ and CD4+
TIL single cell suspensions from 18 freshly-isolated melanoma metastasis (A). 4-1BB
and OX40 was expressed on CD8+, but OX40, was expressed at lower levels on CD8+
TIL (A and B).
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Figure 2.1. Detection of 4-1BB and OX40 on freshly-isolated CD8+ TIL.
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OX40

Addition of agonistic anti-4-1BB antibody increases TIL expansion in vitro. Since
we found that 4-1BB was expressed on our freshly isolated CD8+ TIL, we wanted to
determine whether adding an agonistic anti-4-1BB antibody to our initial isolation of
the TIL would affect the TIL expansion. In our phase II clinical trial at UT MD
Anderson Cancer Center, we are currently only able to successfully grow TIL from
65% of metastatic melanoma patients. In addition, the initial TIL isolation process
can take up to 5 weeks. Since we have previously had success in expanding TIL
CD8+ subsets using this anti-4-1BB antibody (90), we wanted to determine if
activating the 4-1BB pathway using the anti-4-1BB antibody would be able to
increase the number of melanoma patients from which we are able to grow TIL and
decrease the initial TIL isolation time.
Melanoma tumors were surgically resected from patients and cut into 3-5mm2
fragments. The fragments were placed in a 24 well plate over a 3 week period. We
conducted antibody dose titration experiments to test what the optimal concentration
of antibody was (Figure 2.1). Each TIL sample was set up with IL-2 and different
concentrations of anti-4-1BB antibody or IL-2 alone (Figure 2.2A). After 3 weeks,
viable cell counts were done using a hemocytometer after Trypan Blue staining for
each condition (Figure 2.2A). In our clinical trials at UT MD Anderson Cancer
Center (38), we have found that a minimum of 50x106 pre-REP TIL is needed in
order to expand during the secondary expansion (REP) to a sufficient number. We
found that 10µg/ml anti-4-1BB antibody was the optimal dose to expand the pre-REP
TIL to 50x106 after just 3 weeks in culture. Normally, it takes TIL 3-5 weeks to reach
the minimum number (50x106) needed for secondary expansion. We also observed
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that only 65% of metastatic melanoma patients’ TIL grow from the melanoma
fragments. We found that the 10µg/ml anti-4-1BB antibody allowed TIL growth from
some patients whose TIL would not have typically reached the 50x106 threshold
(Figure 2.2B). Since we found our optimal concentration was 10µg/ml anti-4-1BB
antibody, we subsequently added this dose each time the TIL were fed with fresh IL-2
and media and used this concentration for the remainder of our experiments.
Once we found the optimal dose of the anti-4-1BB antibody, we wanted to
determine how the anti-4-1BB antibody would compare to another antibody currently
being used in research and clinical trials at expanding the TIL. We added different
antibodies (anti-4-1BB agonistic antibody, anti-CTLA-4 blocking antibody (Yervoy),
or IL-2 alone control) to the initial TIL cultures and determined cell counts after 3
weeks using a hemocytometer after Trypan Blue staining for each condition (Figure
2.3A). We found that in comparison to anti-CTLA-4, the anti-4-1BB antibody was
superior in expanding the TIL, specifically the CD8+ TIL (Figure 2.3A).
We usually observe the TIL to begin to grow out from the melanoma fragment
after 7 days in culture. We wanted to determine whether the addition of the anti-41BB antibody was inducing more proliferation of the cells that grew out from the
tumor fragment. After 1 week in culture with or without the anti-4-1BB antibody, we
collected the supernatant and cells from the conditions and prepared the samples for
cytospin. We cytospun the cells onto glass slides and stained for the proliferation
marker Ki67 using Immunocytochemistry (ICC) (Figure 2.4A). Interestingly, we
found that as early as 7 days after the initial fragment set-up, the anti-4-1BB antibody
was initiating the TIL to proliferate more than the traditional culture set-up (IL-2)
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(Figure 2.4A). We then went on to investigate the total TIL expansion after a 3 week
period. When we looked at viable cell counts using Trypan Blue and a
hemocytometer, we found that out of 12 independent TIL lines, when the TIL were
grown with IL-2 alone, only 4 out of 12 TIL lines were able to reach the 50x106 TIL
needed for secondary expansion Figure 2.4B. When the TIL were expanded with IL2 and anti-4-1BB antibody, 9 out of 12 independent TIL lines were able to reach the
50x106 TIL threshold needed for secondary expansion Figure 2.4B.
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Figure 2.2. Optimal concentration for pre-REP TIL expansion. A dose titration
experiment was conducted to determine the optimal dose for the anti-4-1BB antibody
for initial TIL expansion. Cells counts were done after 3 weeks of culture for the
different conditions. 50x106 TIL were needed to initiate a successful REP expansion
(dotted, black line). 10ug/ml anti-4-1BB antibody was found to expand the TIL to
over 50x106 and was subsequently the concentration used for the remainder of the
experiments.
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Figure 2.2. Optimal concentration for pre-REP TIL expansion.
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Figure 2.3. Addition of anti-CTLA-4 antibody to the fragments increases the
percentage and expansion of CD4+ TIL. Melanoma tumors were surgically
resected and cut up into multiple fragments and placed in a 24 well plate with IL-2.
The addition of anti-4-1BB antibody, anti-CTLA-4 antibody or the combination of
both was given to the cells each time the cells were fed. After 3 weeks, the TIL were
counted and stained with CD3, CD4, CD8, and a viability dye. The cells were then
gated on the viable, CD3+ population (A). We found that the TIL grown with the antiCTLA-4 antibody (Yervoy) preferentially expanded the CD4+ population, compared
with the TIL expanded with the anti-4-1BB antibody or IL-2 alone (B).
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Figure 2.3. Addition of anti-CTLA-4 antibody to the fragments increases the
percentage and expansion of CD4+ TIL.
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Figure 2.4. Anti-4-1BB agonistic antibody increases TIL expansion in vitro.
When determining the proliferation of the TIL at early time points (1 week in culture),
we found an increased expression of Ki67 proliferation marker in the 4-1BB activated
TIL as compared to the control (A). We then went on to determine the total TIL
expansion after a 3 week period. In order to be eligible for secondary expansion
(REP), the pre-TIL need to reach a minimum of ~50x106 TIL. When we determined
the expansion of the total pre-REP TIL for the different conditions (IL-2 and IL2+anti-4-1BB antibody), we found that 4 out of 12 TIL were able to reach the 50x106
threshold needed to be eligible for secondary expansion when expanded with the anti4-1BB antibody, compared to IL-2 alone.

- 55 -

Figure 2.4. Anti-4-1BB agonistic antibody increases TIL expansion in vitro.
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Activating the 4-1BB pathway increases the CD8+ TIL expansion. We wanted to
determine whether the cells that were growing out of the fragment were CD8+ TIL.
We therefore set up melanoma fragments with or without the addition of 10µg/ml
anti-4-1BB antibody, as described earlier. After 1 week, we collected the cells and
supernatant and prepared the samples for cytospin. The cells were then cytospun onto
glass slides and stained for CD8. We found that the cells grown with IL-2 and the
anti-4-1BB antibody contained more CD8+ cells, compared to the cells that were
grown in IL-2 alone (Figure 2.5A). After the TIL were grown with or without the
anti-4-1BB antibody for 3 weeks, the TIL were stained using flow cytometry for CD3,
and CD8 surface markers. In 48 independent TIL lines, we saw the TIL expanded
with the addition of anti-4-1BB antibody had more CD8+ TIL than the TIL grown
with IL-2 alone (Figure 2.5B).

- 57 -

Figure 2.5. CD8+ TIL percentage is increased with the addition of anti-4-1BB
antibody to TIL cultures. We investigated whether activating the 4-1BB pathway
could augment the percentage of CD8+ TIL in the cultures. After 1 week after the
fragments were set up, we conducted ICC and found that the TIL expanded with IL-2
and anti-4-1BB antibody exhibited an increase in CD8+ cells (A). In a larger scale
(48 independent TIL samples), we found the TIL expanded with the anti-4-1BB
antibody exhibited increased percentages of CD8+ TIL compared to IL-2 control (B).
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Figure 2.5. CD8+ TIL percentage is increased with the addition of anti-4-1BB
antibody to TIL cultures.
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Modulation of melanoma TIL effector phenotype, function, and antigen
specificity by activating the 4-1BB pathway. Melanoma tumors were resected from
patients, cut up into multiple fragments and placed in a 24 well plate with IL-2,
culture media, and with or without the anti-4-1BB antibody. After 3 weeks, the TIL
were stained using flow cytometry for effector-memory markers, markers of effector
cytotoxic T lymphocytes (CTL), and effector function was measured using an ELISA
assay to measure Interferon (IFN)-gamma secretion. In 48 independent TIL lines, we
unexpectedly found that cells grown with the anti-4-1BB antibody had a decreased
percentage of CD27+ TIL in the CD8+ subset (Figure 2.6A). Cells that lose CD27 and
CD28 expression are considered late stage terminally differentiated effector cells that
do not survive or proliferate in the long term (72, 75, 76, 120). When we investigated
the expression of CD70 in the TIL, we found an increase in CD70 expression in the
TIL expanded with the anti-4-1BB antibody (Figure 2.6B). It has been demonstrated
that in an activation-intrinsic event, CD27 expression is decreased in T cells due to
either persistent stimulation or the interaction with CD70 in an activation-independent
situation (121). Further studies need to be done to investigate this further. When we
analyzed the expression of CD28 in the CD8+ TIL subset in 48 independent TIL
samples, we did not detect a difference in CD28 expression in all experimental groups
(Figure 2.6C).
In order to determine whether the TIL that down-regulated CD27 were still
able to expand, the TIL initially grown with or without the anti-4-1BB antibody
underwent the secondary expansion (REP). We found that despite the decreased
CD27 expression during the initial TIL isolation and expansion, the TIL grown with
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anti-4-1BB antibody during the initial expansion expanded at similar levels as the TIL
that were not initially grown with the anti-4-1BB antibody (Figure 2.7A). This
indicated that although the pre-REP TIL down-regulated CD27 expression, they were
not terminally differentiated and were still able to expand during the REP. After the 2
week expansion (REP), the post-REP TIL were phenotyped using flow cytometry for
CD8, CD27, and CD28 cell surface markers (Figure 2.7B-D).
We next investigated the expression of molecules that are associated with
effector CTL and killing function on the TIL. We found an increased expression of
the intracellular expression of the cytolytic granule Granzyme B (Figure 2.8A). We
also investigated the expression of the T-box transcription factor Eomesodermin
(Eomes). Eomes is a regulator of Perforin, Granzyme B and IFN-gamma in CD8+
effector T cells (122, 123). In 19 independent TIL samples, we found that the TIL
grown with the anti-4-1BB exhibited an increased expression of Eomes in the CD8+
subset (Figure 2.8B).
The expression of 4-1BB on antigen-activated CD8+ T cells and the detection
of a significant frequency of 4-1BB+ CD8+ TIL within tumors and during tumor
fragment culture (Figure 2.1), suggests that in addition to enhancing the numerical
expansion of CD8+ TIL through 4-1BB co-stimulation, addition of agonist anti-41BB may also increase the tumor reactivity of the TIL grown out from the treated
fragments. We tested this question in different ways. First, we analyzed the antitumor reactivity of bulk TIL cultures grown out from tumor fragments after 3 weeks
against autologous or HLA-A-matched allogeneic tumor lines by measuring the
extent tumor-specific IFN-gamma release after a 24-h tumor:TIL co-culture assay.
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We found that provision of 4-1BB co-stimulation to the tumor fragments yielded TIL
with markedly higher anti-tumor reactivity after 3 weeks of culture (Figure 2.9A).
Second, we performed Intracellular Cytokine Staining (ICS) for IFN-gamma analysis
of TIL isolated after 3 weeks from fragment cultures and found a significant increase
in the frequency in IFN-gamma+ CD8+ T cells in TIL isolated from fragment cultures
treated with anti-4-1BB antibody (Figure 2.9B). We also measured degranulation
using flow cytometry staining for CD107a. We found that the TIL expanded with IL2 and anti-4-1BB exhibited an increase in CD107a+ in the CD3+CD8+ subset (Figure
2.9C). In addition, in some HLA-A0201+ patients, we stained TIL that grew out from
the fragments for CD8 and MART-1 TCR expression using MART-1 peptide
tetramers and found a marked increase in the frequency of MART-1-specific T cells
when anti-4-1BB was added to the tumor fragment cultures (Figure 2.9D). Finally,
we performed a secondary expansion of TIL isolated from fragment cultures treated
with or without added anti-4-1BB using the REP and analyzed the post-REP cells for
anti-tumor reactivity. Here too, we found an enhanced anti-tumor reactivity of the
post-REP product when 4-1BB co-stimulation was provided in the initial tumor
fragment cultures (Figure 2.9E).
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Figure 2.6. Activation of the 4-1BB pathway augments CD27 and CD70
expression. Fragments from melanoma tumors were set up in a 24 well plate with or
without anti-4-1BB antibody. 3 weeks after the initial set-up, the TIL were harvested
and flow cytometry was done to analyze effector-memory markers and cytolytic
granule markers. CD27 expression in the CD8+ subset was down-regulated in the TIL
grown with the anti-4-1BB antibody as compared to the TIL grown with IL-2 alone
(A). When we investigated the expression of CD70, we found the TIL expanded with
anti-4-1BB antibody exhibited an increase in CD70 expression (B). We found no
statistical significance in the expression of CD28 in the CD8+ subset in the different
conditions (C).
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Figure 2.6. Activation of the 4-1BB pathway augments CD27 and CD70
expression.
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Figure 2.7. TIL initially expanded with anti-4-1BB antibody continue to expand
during secondary expansion in the REP. After TIL were initially expanded with or
without anti-4-1BB antibody, the pre-REP TIL were then subjected to the REP. After
the 2 week expansion, phenotype analysis and cell counts were conducted. Post-REP
TIL initially expanded with anti-4-1BB antibody exhibited increased CD8+
expression (A) and similar levels of CD27 (B) and CD28 (C). Total (D) and CD8 (E)
fold expansion was not disrupted despite the loss of CD27 at the pre-REP level in the
TIL expanded with anti-4-1BB antibody.
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Figure 2.7. TIL initially expanded with anti-4-1BB antibody continue to expand
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Figure 2.8. Activation of the 4-1BB pathway augments effector cell phenotype
and function. We found the expression of the cytolytic granule marker Granzyme B
(A) was increased in the TIL expanded with IL-2 and anti-4-1BB antibody as
compared to TIL expanded with IL-2 alone. Eomes is a regulator of Granzyme B,
Perforin, and IFN-gamma. When we measured the expression of Eomes using flow
cytometry, we found the TIL expanded with the anti-4-1BB antibody exhibited
increased Eomes expression in the CD8+ subset (B).
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Figure 2.8. Activation of the 4-1BB pathway augments effector cell phenotype.
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Figure 2.9. Increased tumor reactivity in TIL expanded with anti-4-1BB
antibody. After the fragments were set up with IL-2 alone or IL-2 plus anti-4-1BB
antibody and expanded over a 3 week period (pre-REP), the TIL were harvested and
set up at a 1:1 ratio with autologous (A) tumor cells. Supernatants were collected after
24 hours and IFN-gamma secretion was measured. We demonstrated in 2 independent
pre-REP TIL that IFN- gamma secretion was increased in the pre-REP TIL expanded
with IL-2 and anti-4-1BB compared to TIL expanded with IL-2 alone (A). After 3
week in culture with or without the anti-4-1BB antibody, the TIL were set up at a 1:1
ratio with HLA-A matched tumor lines. Using flow cytometry, we measured the
amount of IFN-gamma+ cells in the CD3+CD8+ subset (B). We found that the TIL
expanded with anti-4-1BB antibody exhibited an increase in IFN-gamma+ cells (B).
In addition, we also used flow cytometry to determine the amount of degranulation
after setting up the TIL at a 1:1 ratio with HLA-A matched tumor lines (C). We found
that the TIL grown with the anti-4-1BB antibody exhibited an increase in CD107a+
cells in the CD3+CD8+ subset (C). Using flow cytometry, we measured the
percentage of MART-1+ specific T cells on the CD3+ CD8+ TIL initially expanded
with IL-2 alone or IL-2 with anti-4-1BB antibody. We found that the TIL expanded
with the anti-4-1BB antibody exhibited an increase in antigen specific population,
compared to the TIL expanded with IL-2 alone (D). The pre-REP TIL that were
initially expanded with or without the anti-4-1BB antibody then underwent the
secondary expansion (REP). After the 2 week expansion, the post-REP TIL were
harvested and set up at a 1:1 ratio with the autologous tumor (E left) or HLAmatched (E middle and right) tumor cells. 24 hours later, the supernatants were
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collected and IFN-gamma secretion was measured using ELISA. The post-REP TIL
that were initially expanded with anti-4-1BB antibody exhibited an increase in
Interferon-gamma secretion compared to the TIL initially expanded with IL-2 alone
(E).
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Figure 2.9. Increased tumor reactivity in TIL expanded with anti-4-1BB
antibody.
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2.3 Discussion
Although ACT has been shown to be an effective therapy for later stage
melanoma patients that have failed first and second line therapies, investigators are
still trying to find innovative ways to improve the therapy and overall response rates.
Our results demonstrate a novel approach using an agonistic anti-4-1BB antibody to
expand the melanoma TIL during the initial isolation from the tumor fragment. Not
only were we able to grow more TIL, allowing for a potential increase the amount of
patients eligible for secondary expansion, but we were able to grow these large
numbers of TIL in a shorter amount of time (2-3 weeks compared to the traditional 45 weeks needed). We found that the anti-4-1BB antibody not only expands TIL in a
shorter amount of time, but these TIL were mainly CD8+ that expressed cytolytic
granule marker Granzyme B, and were tumor reactive against autologous tumors or
HLA-A matched tumor lines.
Another important finding that we have consistently seen using the anti-41BB antibody during the melanoma expansion is that the anti-4-1BB antibody
specifically expands CD8+ TIL. This is exciting for us because we have found that the
more CD8+ TIL infused into melanoma patients, the better the patient’s clinical
response. However, it is important to understand the mechanism behind this
phenomenon.
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CHAPTER 3

Understanding the role of 4-1BB activation during initial TIL
isolation from metastatic melanoma tumor fragments
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3.1 Rationale and Hypothesis
Our initial observation was that activating the 4-1BB pathway using an
agonistic anti-4-1BB antibody increased the TIL proliferation, expansion, CD8+
output and effector phenotype and functionality. In our second Aim, we wanted to
gain a deeper insight as to how the anti-4-1BB antibody was working to induce a
better TIL product during the initial expansion. We observed that TIL expanded using
the enzymatic digest approach exhibited no difference in total cell growth when
expanded with anti-4-1BB antibody. However, when the TIL were expanded from
melanoma fragments, the anti-4-1BB antibody greatly enhanced the outgrowth of the
TIL in a shorter amount of time, as compared to when the TIL were grown with IL-2
alone. This initial observation prompted us to hypothesize that the environment
(other cells and cytokines) within the melanoma fragment was playing a role during
the initial TIL isolation.
When the 4-1BB pathway is activated, in our case, by using an agonistic
antibody, it signals through the TRAF complex to activate the NFκB pathway, as well
as other key signaling pathways, such as PI3K/AKT, which can directly control the
expression of anti-apoptotic genes, such as Bcl-xL, and bcl-2 (87, 89).
We examined other possible mechanisms of action and found that resident
dendritic cells (DC) in the tumor fragments survive for considerable periods of time
and also express 4-1BB. These tumor fragment resident DC also activate NFB, and
up-regulate certain maturation markers with 4-1BB agonist addition. In addition, we
examined whether ongoing HLA class I antigen presentation occurs in the early
tumor fragment cultures that may enhance the output of CD8+ TIL. We found that
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addition of a blocking anti-HLA class I antibody reduced the output of CD8+ TIL,
especially with anti-4-1BB, suggesting that continual antigen presentation occurs ex
vivo in these early tumor fragment cultures that was not considered before.
STAT5 binding sites have been identified in promoter region of 4-1BB and 41BB expression can be modulated by IL-2R signaling through STAT5 activation
(124). Therefore, we investigated whether 4-1BB activation augmented the STAT5
pathway in our initial TIL cultures. We found that when the TIL were expanded with
anti-4-1BB, the pSTAT5 expression was increased, compared to the TIL grown with
IL-2 alone. Bcl-6 has also been important for the maintenance of CD8+ T cells (122,
123) and when we investigated the expression of bcl-6 in our TIL, we found that the
TIL grown with the anti-4-1BB antibody exhibited an increase in bcl-6 expression.
In conclusion, activating the 4-1BB pathway during the initial TIL isolation
induces the TIL to become more activated, and also the DCs to become more active
and secrete more pro-inflammatory cytokines that may activate the TIL, causing their
migration out of the tumor fragment at a faster rate than the TIL without the anti-41BB antibody. Pro-inflammatory factors can also promote long-term survival of
antigen-specific T cells in vivo.
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3.2 Results
TIL require additional activation to respond to anti-4-1BB antibody during
initial TIL isolation.
When we set up our initial TIL cultures, we can either set up fragments from
the melanoma tumor or we can conduct an enzymatic digest using collagenase,
hyaluronidase, and Ficoll (Figure 3.1). The fragment set up includes cutting the
melanoma fragment into multiple fragments, expecting the TIL to grow out from the
fragment by adding IL-2 over a 4-5 week period. The T cells are not only in contact
with other T cells, but the cells within the melanoma fragment. However, when an
enzymatic digest is done using Ficoll, the TIL are separated into a single layer
(Figure 3.1). The enzymatic digest helps the TIL to grow separately from the rest of
the cells within the tumor, making the T cells more prone to induce activation by Tcell to T-cell interaction. When we first conducted our experiments, we set up the TIL
cultures using the enzymatic digest protocol in parallel to the fragment set up.
Surprisingly, we found that when we set up the TIL cultures using the enzymatic
digest, there was no difference in TIL proliferation (Figure 3.2A), compared to the
TIL that were expanded with the anti-4-1BB antibody (Figure 3.2B).
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Figure 3.1. Process of TIL isolation from melanoma tumors. Melanoma tumors
are surgically resected from metastatic melanoma patients. The tumors are then cut up
and enzymatically digested using Collagenase, Hyaluronidase, DNAse I, and Ficoll.
This approach results in the physical separation of the TIL from the tumor cells. The
other approach to isolate the TIL from the melanoma tumor is cutting up the
melanoma tumor into multiple fragments. The TIL are in direct contact with other
TIL as well as the other factors within the microenvironment that may influence their
outgrowth from the fragment. The TIL are then expanded over a 4-5 week period
with high-dose IL-2 and media.
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Figure 3.1. Process of TIL isolation from melanoma tumors.
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Figure 3.2. TIL isolated using enzymatic digest do not expand better with the
anti-4-1BB antibody. The TIL were initially isolated from the melanoma tumor
using 2 different methods. The first method uses enzymes to digest the tumor and
subsequently separates the TIL layer (A). The second method involves cutting up the
melanoma fragment in 3-5mm2 pieces and placing one fragment per well in a 24-well
plate (B). The TIL isolated from both methods were subsequently placed in a 24-well
plate and fed with IL-2±anti-4-1BB antibody and media over a 3 week period. After
the 3 week period, the viable TIL were counted. We found that the TIL isolated using
the enzymatic approach exhibited no difference in TIL growth when expanded with
or without the anti-4-1BB antibody (A). However, when the melanoma tumor was cut
up into multiple fragments, the TIL expanded much better when grown with the anti4-1BB antibody compared to IL-2 alone (B). The dotted line represents the 50x106
TIL threshold needed to be eligible for the TIL to undergo the secondary expansion
(REP).
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Figure 3.2. TIL isolated using enzymatic digest do not expand better with the
anti-4-1BB antibody.
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Proposed hypothesis for the role of the anti-4-1BB antibody within the
melanoma fragment. Our finding that the TIL grow better with the anti-4-1BB
antibody when fragments are set up prompted us to form a hypothesis that the
environment and/or cells within the melanoma fragment were playing a key role in
activating and making the TIL more prone to proliferate and expand with the anti-41BB antibody (Figure 3.3). We hypothesized that when the anti-4-1BB antibody was
added to the fragments, the TIL were becoming more responsive and activated,
proliferating more and secreting more IFN-gamma either through direct TCR
interaction or cytokines secreted by other cells within the melanoma fragment that
were also getting activated by the anti-4-1BB antibody (Figure 3.3). When IL-2 alone
was given, the cells within the fragment may or may not become activated, become
anergic or undergo apoptosis, resulting in the TIL not being as activated or responsive
(Figure 3.3).
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Figure 3.3. Proposed role for 4-1BB activation within the melanoma fragment.
We proposed that cells or other factors, such as cytokines, within the melanoma
fragment activate the TIL to proliferate and migrate out of the tumor. Some cells
within the fragment express 4-1BB and may be responsive to the anti-4-1BB antibody,
further activating the TIL to migrate out of the tumor.
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Figure 3.3. Proposed role for 4-1BB activation within the melanoma fragment.
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B cell

Blocking the MHC class I inhibits CD8+ TIL expansion during initial TIL
isolation. We first wanted to test our hypothesis by determining whether the T-cell
receptor (TCR) interaction was crucial in inducing the TIL to expand during their
initial isolation from the melanoma fragment. We tested this by adding an anti-human
HLA-ABC blocking antibody that recognizes a non-polymorphic epitope shared by
the products of HLA-A, B, and C loci (www.ebioscience.com/human-hla-abcantibody-biotin-w6-32.htm) during the initial TIL isolation. When we added the antiHLA-ABC blocking antibody, we found that the CD8+ TIL expansion was greatly
decreased, compared to the TIL grown with IL-2 alone or IL-2+anti-4-1BB antibody
(Figure 3.4).
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Figure 3.4. Blocking the MHC class I inhibits TIL recovery during initial TIL
isolation. The melanoma tumor was surgically resected and cut up into multiple
fragments. The fragments were then placed in an anti-HLA-ABC blocking antibody
(anti-HLA ab) at a concentration of 80µg/ml for 3 hours at 37°. After, the fragments
were then given anti-4-1BB antibody or IL-2 alone. The cultures were subsequently
fed with additional anti-MHC antibody once more and all cultures were fed over a 3
week period with media, IL-2± anti-4-1BB antibody. After, the viable cells were
counted and stained for CD3 and CD8. When the anti-HLA-ABC antibody was added
to the cultures, the CD8+ cell count was greatly decreased compared to the IL-2+anti4-1BB condition.
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Figure 3.4. Blocking the MHC class I inhibits TIL recovery during initial TIL
isolation.
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4-1BB is expressed on different cell subsets in the melanoma fragments.
We next wanted to investigate whether the TIL were being activated by other
cells within the fragment. The melanoma tumors were cut up into multiple fragments
and placed in culture with IL-2. After 1 week, the fragment was mechanically
disaggregated, filtered, and stained for different immune cell subsets (Dendritic cells,
NK cells, B cells and T cells) that are known to express 4-1BB (110). We found that
the expression of 4-1BB was in the CD8+ TIL subset (Figure 3.5A and B) as shown
in 2 representative TIL lines (Figure 3.5A) and in 7 TIL patient samples (Figure
3.5B). OX40 was also expressed in the CD8+ subsets (Figure 3.5A) as demonstrated
in 2 TIL lines (Figure 3.5A) and in 5 TIL patient samples (Figure 3.5B), but to a
lesser extent than 4-1BB.
4-1BB can be expressed on Dendritic cells (DCs), Natural Killer (NK) cells, B
cells and T cells (110). Therefore, we targeted these main populations in the
melanoma tumor fragment to determine if they expressed 4-1BB. We found that the
population of B cells was less than 0.5% in the total population (Figure 3.6A). When
we looked at the CD3- population, we did not find any statistically significant
changes in the NK cell markers or 4-1BB expression in the cultures expanded with or
without anti-4-1BB antibody (Figure 3.6B).
When we determined the expression of 4-1BB in the DC subset, we found that
indeed, the DCs did express 4-1BB (Figure 3.7) as shown in 2 independent TIL lines.
Interestingly, we found that in the cultures where anti-4-1BB antibody was added,
when we gated on dendritic cells, there was an increase expression of MHC-II, CD80
and CD86 expression, and the DCs expressed 4-1BB (Figure 3.8 and Figure 3.9). It
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has been demonstrated that DCs within a hypoxic microenvironment have decreased
activation and maturation markers and down-regulation of pro-inflammatory
cytokines (125). However, treatment with an anti-4-1BB antibody increased the
expression of pro-inflammatory cytokines and maturation markers in the DCs that
were in the hypoxic environment (125). 4-1BB has been shown to be expressed on
DCs (113). In another study, when 4-1BB was ligated on the DCs using an agonistic
antibody, this resulted in the DCs secreting more pro-inflammatory cytokines and the
increased ability to stimulate T cells (113, 126). In addition, we also found that the
addition of anti-4-1BB antibody to the cultures increased pro-inflammatory cytokines
IFN-gamma, TNF-alpha, and IL-6 (Figure 3.10). 4-1BB was also found to function
as a survival factor in DCs. DCs that were 4-1BB-/- had an impaired survival rate,
resulting in decreased levels of anti-apoptotic molecules, such as bcl-2 and bcl-xL, as
compared to 4-1BB+/+ DCs (113, 126).
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Figure 3.5. Expression of 4-1BB in the T-cell population within the melanoma
tumor fragment. We set up the melanoma tumor fragments with IL-2 over a 7 day
period. We saw that on day 7, the 4-1BB was still expressed in the CD8+ subsets
within the melanoma tumor fragment as demonstrated in 2 TIL patient samples (A)
and in 7 TIL patient samples (B). We found another TNFR super family member
OX40 was also expressed in the CD8+ subsets, as demonstrated in 2 TIL patient
samples (A) and in 5 patient TIL samples (B), but to a lesser extent than 4-1BB.
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Figure 3.5.Expression of 4-1BB in the T-cell population within the melanoma
tumor fragments.
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Figure 3.6. Staining for B cells and NK cells in melanoma fragment. The
melanoma tumor was cut up into multiple fragments, placed in a 24-well plate with
media and IL-2± anti-4-1BB antibody. Each condition (IL-2 or IL-2+anti-4-1BB
antibody) contained 4 individual fragments to ensure sufficient cell numbers for flow
cytometry staining. On day 7 of the cultures, the 4 fragments were pooled from the
IL-2 alone condition, mechanically disaggregated, and stained for CD3, 4-1BB, CD56,
CD19, and CD20. The same method was applied to the IL-2+anti-4-1BB condition in
parallel. There was a very small percentage of B cells after 7 days (A). Although
there was an NK cell population in the fragments, there was no difference in the
expression of 4-1BB or the expression of CD56 in the NK population when the
fragments were grown with or without anti-4-1BB antibody (B).
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Figure 3.6.Staining for B cells and NK cells in melanoma fragments.
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B)

Figure 3.7 Expression of 4-1BB in DCs in melanoma fragment. The melanoma
fragments were set up with or without addition of anti-4-1BB antibody. In 2
representative TIL samples, we found that 4-1BB was expressed in DCs within the
melanoma fragments.
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Figure 3.7: Expression of 4-1BB in DCs in melanoma fragment.
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4-1BB ligation induces activation of dendritic cells within melanoma fragment.
Since we observed that 4-1BB was expressed on dendritic cells, we wanted to
investigate whether 4-1BB ligation via the anti-4-1BB antibody could induce
activation of the DCs. Studies have previously showed that dendritic cells within a
hypoxic environment are susceptible to undergo apoptosis. However, when costimulation was provided to these DCs using an agonistic anti-4-1BB antibody, the
DCs were able to secrete more pro-inflammatory cytokines and increase their
activation markers. DCs isolated from 4-1BB-/- mice survived less that DCs isolated
from 4-1BB+/+ mice.
For our studies, melanoma tumors were surgically extracted from patients.
The tumors were then cut up into multiple fragments and placed in culture with media,
IL-2±anti-4-1BB antibody. The fragment was mechanically disaggregated, filtered,
and stained for CD3, CD11c, MHC II, CD80, CD86, and 4-1BB. We show in 1
representative TIL flow cytometry contour plot that the DCs express 4-1BB and that
adding the anti-4-1BB antibody to the culture increased DC activation markers
(Figure 3.8A). When we looked at the activation markers in multiple patient samples,
activation of 4-1BB via the anti-4-1BB antibody increased activation markers in the
DCs within the fragment (Figure 3.8B). In Figure 3.8C, we demonstrate in 5
independent TIL lines, that DCs express 4-1BB at varying levels. Patient TIL and
tumors vary from patient to patient, therefore we decided to determine whether the 41BB ligation induced the activation markers in DCs in a number of TIL lines.
We also investigated whether adding the anti-4-1BB antibody during the
initial cultures was inducing the DCs to secrete more pro-inflammatory cytokines. We
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conducted a Meso -Scale Discovery (MSD) assay and found that when anti-4-1BB
antibody was added to the cultures, there was an increase in IFN-gamma, Interleukin6 (IL-6), and TNF-alpha (Figure 3.9).
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Figure 3.8. Increased activation markers in DCs when 4-1BB pathway is
activated. The melanoma tumor was surgically removed and cut up into multiple
fragments and placed into culture with TIL media and IL-2± anti-4-1BB antibody in a
24-well plate. Each condition contained 4 individual fragments that were pooled on
day 7. After 7 days, the 4 fragments per condition were pooled, mechanically
disaggregated, filtered, and stained for MHC-II, CD11c, CD80, CD86, 4-1BB, and a
viability dye using flow cytometry. We found that the cultures that anti-4-1BB
antibody was added induced an increase in MHC-II, CD80 and CD86.
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Figure 3.8. Increased activation markers in DCs when 4-1BB pathway is
activated.
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Figure 3.9. Increased pro-inflammatory cytokines after addition of 4-1BB
antibody during initial TIL expansion. The melanoma tumor was cut up into
multiple fragments and placed in culture with IL-2±anti-4-1BB antibody. After 1
week, the supernatant from the two different conditions was collected and Meso Scale
Discovery (MSD) was performed to measure the cytokines secreted in the cultures.
The secretion of Interferon-gamma (A), IL-6 (B), and TNF-alpha (C) were increased
in the cultures where anti-4-1BB antibody was added.
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Figure 3.9. Increased pro-inflammatory cytokines after addition of 4-1BB
antibody during initial TIL expansion.
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Activating the 4-1BB pathway increases NFκB translocation in TIL and DCs
within the melanoma fragment.
4-1BB signals through the TRAF complex to activate the NFκB pathway,
which can then directly control the expression of anti-apoptotic genes, such as Bfl-1,
Bcl-xL, and bcl-2 (Figure 1.6). The fragments were set up as previously described,
with or without the anti-4-1BB antibody. After 1 week, the fragments were collected,
mechanically disaggregated between 2 glass slides, filtered, and stained for NFκB
(p65) and IκBα in the TIL (Figure 3.10A and B) and DC subsets (Figure 3.11) using
flow cytometry. In addition, the TIL proliferation was also measured using Ki67
(Figure 3.10C). We found that the addition of anti-4-1BB antibody to the fragments
induced NFκB (p65), while decreasing IκBα in both the TIL (Figure 3.10A and B)
and DC subsets (Figure 3.11). We also observed that the TIL were proliferating
more when the anti-4-1BB antibody was added to the cultures (Figure 3.10C).
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Figure 3.10. Modulation of NFκB in T cells within melanoma fragment with 41BB pathway activation. Melanoma tumors were surgically resected from late stage
melanoma patients. The tumors were then cut up into multiple fragments and placed
in a 24-well plate with IL-2±anti-4-1BB antibody. Each condition contained 4
individual fragments to ensure sufficient numbers of cells would be collected for
staining. After 1 week, the 4 fragment per condition were pooled and mechanically
disaggregated, filtered, and stained for CD3, CD8, NFκB (p65), IκBα, and Ki67 using
flow cytometry. When the anti-4-1BB antibody was added to the cultures, the T cells
within the melanoma fragment exhibited increased NFκB and proliferation (Ki67) (A
and C). The increased NFκB correlated with the decreased IκBα expression seen in
the TIL expanded with the anti-4-1BB antibody (B).
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Figure 3.10. Modulation of NFκB in T cells within melanoma fragment with 41BB pathway activation.
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Figure 3.11. Modulation of NFκB in DC subset with melanoma fragment after 41BB activation. After the melanoma fragments were set up for a week with or
without anti-4-1BB antibody, the fragment was collected, mechanically disaggregated,
filtered, and stained for NFκB (p65) and IκB using flow cytometry. 4-1BB ligation
can induce signaling through the NFκB pathway and we wanted to investigate
whether this is occurring in the DC subset within the melanoma tumor. We found that
when we added the anti-4-1BB antibody to the cultures, NFκB (p65) was increased in
parallel to IκB decreasing in the DCs.
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Figure 3.11. Modulation of NFκB in DC subset with melanoma fragment after 41BB activation.
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Addition of anti-4-1BB antibody to the cultures decreases 4-1BB expression but
increases NFκB translocation in the T cells migrating out of the melanoma
tumor fragment.
When we looked early on in the culture (1 week), we found that the cultures
grown with the anti-4-1BB antibody exhibited more cell proliferation in the TIL
(specifically CD8+ TIL) migrating out of the tumor (Figure 2.4A). We wanted to
determine whether the expression of surface and intracellular 4-1BB was modulated
when the 4-1BB pathway was activated. We set up the melanoma fragments with IL2 ± anti-4-1BB antibody over a period of 7 days. On day 2, 4, and 7, we collected the
cells that had migrated out of the fragment, filtered them, and stained for CD3, CD4,
CD8, 4-1BB, and a viability dye using flow cytometry. We found that the expression
of surface 4-1BB was decreased in the CD4+ and CD8+ subset when anti-4-1BB
antibody was added to the cultures over the period of 7 days (Figure 3.12A top) and
in 4 independent TIL on day 7 (Figure 3.12A bottom). Interestingly, when we
stained for 4-1BB in the intracellular compartment, we found that the expression was
increased when the TIL were grown with the anti-4-1BB antibody compared to IL-2
alone (Figure 3.12B).
It has been previously demonstrated that when 4-1BB is ligated, it can signal
through the TRAF complex to activate the NFκB pathway, which can then directly
control the expression of anti-apoptotic genes, such as Bfl-1, Bcl-xL, and bcl-2
(Figure 1.5). The fragments were set up as previously described, with or without the
anti-4-1BB antibody. After 1 week, the cells and supernatant were collected and
prepared for cytospin. The samples were then cytospun onto glass slides and stained
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for NFκB (p65). We observed that the TIL grown with IL-2 and the anti-4-1BB
antibody exhibited more NFκB translocation in the nucleus as compared to the TIL
grown in IL-2 alone (Figure 3.13A and Figure 3.13B). When we looked at NFκB
(p65) activation in the TIL using flow cytometry, we found that the TIL exhibited an
increase in NFκB and a decrease in IκBα in the CD3+CD8+ subset (Figure 3.13C).
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Figure 3.12. Expression of 4-1BB on the T cells migrating out of the tumor. The
melanoma fragments were cut up and placed in TIL media, IL-2± anti-4-1BB in a 24well plate over a period of 7 days. After 2, 4, and 7 days, the fragment was removed,
mechanically disaggregated, filtered and stained as mentioned earlier. After the
fragment was removed, the remaining supernatant and cells that migrated out of the
tumor fragment were collected, filtered, and stained for a viability dye, CD3, CD8,
CD4, and 4-1BB expression using flow cytometry. The cultures that were expanded
with IL-2 and IL-2+anti-4-1BB antibody exhibited 4-1BB expression in the CD4+ and
CD8+ subsets over the 7 day period (A top). On day 7, we measured the 4-1BB
expression in 4 independent TIL lines in the CD8+ and CD4+ subsets (A bottom).
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Figure 3.12. Expression of 4-1BB on the T cells migrating out of the tumor.
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8

Figure 3.13. Increased NFκB translocation in TIL grown with the anti-4-1BB
antibody. Melanoma fragments were set up as described in the Methods section with
or without anti-4-1BB antibody. After 1 week, the cells were collected and cytospin
and Immunocytochemistry were done. Staining for NFκB (p65) revealed more
translocation in the nucleus of TIL grown with IL-2 and the anti-4-1BB antibody
compared to TIL grown with IL-2 alone. We used Vectra Intelligents slide analysis
system (Nuance software) (A) to observe the translocation of NFκB (red is nucleus;
green is NFκB; and yellow is overlay (translocation). The red arrow indicates one
area where translocation occurred. Quantification of NFκB translocation in 10
different areas per sample is demonstrated in 3 independent TIL samples (B). When
we determined NFκB (p65) activation using flow cytometry, we found NFκB
increased in the CD3+ CD8+ subset and a decrease in IκBα in the CD3+CD8+ subset
when the TIL were expanded with IL-2+anti-4-1BB antibody compared to IL-2 alone
(C).
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Figure 3.13. Increased NFκB translocation in TIL grown with the anti-4-1BB
antibody.
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4-1BB ligation modulates pAKT and increases pSTAT5 in the CD8+ subset
during the initial TIL expansion.
Since we found that activating the 4-1BB pathway was inducing more NFB
translocation in the TIL, we decided to investigate other signaling pathways and
molecules that may play a role in the TIL activation. It has previously been reported
that using an agonistic antibody of 4-1BB (3H3) promoted the activity of Akt in
CD8+ T cells (127). In addition, co-stimulation by 4-1BB has been shown to inhibit
T-cell apoptosis and induce Bcl-xL via PI3K and AKT/protein kinase B (128). We
therefore decided to investigate whether activating the 4-1BB pathway to expand
melanoma TIL was activating the AKT pathway. We indeed found that activating the
4-1BB pathway was increasing pAKT in the CD8+ TIL subset (Figure 3.14).
Since we have previously demonstrated that activating the 4-1BB pathway
induces increased levels of anti-apoptotic molecules, such as bcl-2 (86, 90), we
decided to investigate what could be regulating the bcl-2 expression. It has been
reported that activation of 2 primary pathways, the JAK/STAT pathway and the
PI3K/AKT pathway results in increased levels of bcl-2. We next wanted to focus on
the STAT pathway and specifically focus on STAT5. We investigated STAT5
because it has been demonstrated that bcl-2 is a target of STAT5, there have been
STAT5 binding sites identified in the promoter region of 4-1BB, and TNFR super
family members 4-1BB, OX40, and GITR have their expression modulated by IL-2R
signaling through the activation of STAT5 (124). We found that expanding the TIL
with the anti-4-1BB pathway increased the pSTAT5 level in the CD8+ subset (Figure
3.15A).
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Since we add IL-2 to our cultures, we wanted to investigate whether the TIL
expanded with anti-4-1BB were more responsive to IL-2.Therefore we measured
CD25, which is the IL-2 receptor alpha chain. We found that when anti-4-1BB
antibody was added to the TIL, there was an increase in CD25, compared to when IL2 alone was added (Figure 3.15B).
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Figure 3.14. The addition of the anti-4-1BB antibody modulates pAKT in the
CD8+ subset during the initial TIL expansion. The melanoma tumor was cut up
into multiple fragments and placed in a 24-well plate with media and IL-2±anti-41BB antibody. After 3 weeks in culture, the cells were harvested and stained for CD3,
CD8, and pAKT using flow cytometry. The percentage and Mean Fluorescence
Intensity (MFI) of the CD8+ subset was slightly increased in the cells expanded with
anti-4-1BB antibody but was not statistically significant.
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Figure 3.14. The addition of the anti-4-1BB antibody modulates pAKT in the
CD8+ subset during the initial TIL expansion.
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Figure 3.15. Activating the 4-1BB pathway during initial TIL expansion
increases pSTAT5 and CD25. The TIL were initially expanded with or without anti4-1BB antibody for 3 weeks. After, the TIL were harvested and stained for CD3, CD8,
pSTAT5 (A) and CD25 (B). The TIL expanded with anti-4-1BB antibody exhibited
an increase in (A) STAT5 and CD25 (B) percentage and MFI in the CD3+CD8+
subset.
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Figure 3.15. Activating the 4-1BB pathway during initial TIL expansion
increases pSTAT5.
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Increased bcl-2, bcl-6 and Eomes expression in TIL initially expanded with anti4-1BB antibody.
Bcl-2 is an anti-apoptotic molecule that is associated with cell survival. When
we measured the expression of bcl-2 in the TIL expanded with anti-4-1BB antibody,
we observed an increase in the bcl-2 (Figure 3.16A). Since we have found that
activating the 4-1BB pathway increased Eomes expression (Figure 2.8B and Figure
3.16C) and induce the expansion of CD8+ TIL, we wanted to further investigate this.
Bcl-6 and Eomes have been implicated to be major regulators in the differentiation
and subsequent survival status of memory cell (129, 130). Bcl-6 has been determined
to be crucial for the maintenance of activated CD8+ cells during memory stage (129,
130). In addition, it has been demonstrated that Bcl-6 controls Granzyme B
expression in CD8+ T cells and controls the generation and maintenance of CD8+ T
cells (129-131). Specifically in B cells, STAT3 and STAT5 have been shown to
regulate Bcl-6 (132). When we examined the level of bcl-6 after expanding the TIL
with or without the anti-4-1BB antibody for 3 weeks, we found that the expression of
bcl-6 was increased in the CD8+ subset when we activated the 4-1BB pathway
(Figure 3.16B).
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Figure 3.16. 4-1BB ligation induces the expression of bcl-2, bcl-6, and Eomes.
The TIL were expanded from the melanoma fragment with IL-2±anti-4-1BB antibody
for a period of 3 weeks. After, the TIL were then stained for CD3, CD8, Eomes, bcl-2
and bcl-6. We found that the TIL grown with the anti-4-1BB antibody exhibited an
increased bcl-2 (A), bcl-6 (B), and Eomes (C) percentage and MFI in the CD3+CD8+
subset compared to the TIL expanded with IL-2 alone.
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Figure 3.16. 4-1BB ligation induces the expression of bcl-2, bcl-6 and Eomes.
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3.2 Discussion
When we initially isolate the TIL from the melanoma fragment, there are 2
ways this can be done. The first way is to cut up the melanoma tumor into multiple
fragments and place in media and IL-2 over a period of 4-5 weeks. The second way to
isolate the TIL is to use enzymatic digestion. This allows the T cells to become
physically separated from the tumor cells and other cells within the fragment. The
TIL are placed in media with IL-2 over a period of 4 weeks. We initially isolated the
TIL using both methods in parallel. Interestingly, we found that only the TIL
expanded from the melanoma fragment grew better when the anti-4-1BB antibody
was added. This prompted us to investigate whether the anti-4-1BB antibody was
having an effect on the other cells within the melanoma fragment as 4-1BB is
expressed on a number of cells (T cells, DCs, B cells, and NK cells).
We found that activating the 4-1BB pathway induced an increase in proinflammatory cytokines. Pro-inflammatory factors can induce the proliferation of
antigen-specific cells. The antibody may also be inducing the dendritic cells to
become more activated, secreting pro-inflammatory cytokines and stimulate the T
cells within the melanoma fragment, inducing the T cells to migrate out of the tumor
faster and proliferate better (Figure 3.8 and 3.11).
When 4-1BB is ligated, it signals through a TRAF complex to initiate
downstream signaling pathways that result in the increase of anti-apoptotic molecules,
such as bcl-2 and bcl-xL. We first investigated the modulation of the AKT pathway in
the CD3+ CD8+ subset. After 3 weeks in culture, we harvested the TIL, stained for
pAKT and found that although there appeared to be an increase in pAKT, it was not
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statistically significant. This may be due to the low number of TIL lines (N), but
further work needs to be done to investigate this. 4-1BB expression is modulated by
IL-2R signaling through STAT5 activation and STAT5 binding sites identified in
promoter region of 4-1BB (124).
Bcl-6 has been determined to be crucial for the maintenance of activated
CD8+ cells during memory stage (129, 130). Bcl-6 and Eomes are important
regulators of the differentiation of memory cells and the subsequent survival of these
cells (122, 123, 129, 130). We determined the expression of bcl-6 and Eomes after 3
weeks, we found that the TIL expanded with the anti-4-1BB antibody exhibited an
increase in bcl-6 and Eomes.
Our data suggests that very early during the initial TIL isolation and
expansion, the TIL need to be activated in order to proliferate better and migrate out
of the tumor faster with IL-2+anti-4-1BB antibody. When the TIL are grown with IL2 alone, there is a higher possibility that the TIL will not reach the 50x106 total TIL
count needed to undergo secondary expansion as compared to when the TIL are
grown with IL-2 + anti-4-1BB antibody. The TIL that receive IL-2 alone may not be
getting activated through other T cells or through the DCs as they are when 4-1BB
ligation is occurring (Figure 3.17).
Our results indicate that tumor fragments placed in culture to expand TIL for
adoptive cell therapy are not static tissues, but small, dynamic tumor
microenvironments that can be manipulated to alter the yield and phenotype of TIL
being expanded for cell therapy as well as enrich for tumor reactivity and improved
memory phenotype. The use of 4-1BB co-stimulation enhancement in this system can
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be the first of many ways to manipulate these ex vivo tumor microenvironments to
develop protocols to expand optimally active TIL for adoptive cell therapy.
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Figure 3.17. Proposed model for 4-1BB activation during initial TIL expansion.
We observed that the TIL initially isolated and expanded from the melanoma
fragment were expanding much faster and to a greater extent when 4-1BB ligation
was occurring. Since we did not observe this trend when we isolated the TIL using an
enzymatic digest, we hypothesized that the environment within the fragment may be
playing a role to expand the TIL when 4-1BB ligation is occurring since many cells
can express 4-1BB. We observed that when the anti-4-1BB antibody was added to the
cultures, the DCs had an increase in MHC-II, CD80 and CD86. 4-1BB ligation is also
known to increase the cytokines secreted by DCs that may also activate T cells. We
believe that 4-1BB ligation is activating the DCs and either directly activating the TIL
or indirectly through cytokines, resulting in the TIL to proliferate more and migrate
out of the fragment at a faster rate than when 4-1BB ligation goes not occur.
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Figure 3.17. Proposed model for 4-1BB activation during initial TIL expansion.
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CHAPTER 4

Co-stimulation Through 4-1BB/CD137 Improves the Secondary
Expansion and Function of CD8+ Melanoma Tumor-infiltrating
Lymphocytes for Adoptive T-cell Therapy
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4.1 Rationale and Hypothesis
Adoptive T-cell therapy (ACT) has emerged as the most powerful
immunotherapy for stage IIIc-IV metastatic melanoma. ACT involves the use of
expanded tumor-infiltrating lymphocytes (TIL). CD8+ T cells have been found to be
critical in mediating tumor regression during ACT. TIL expansion occurs in two
phases: the first phase initially expands TIL from excised tumor pieces with IL-2 and
this phase is followed by a rapid expansion protocol (REP) in which the TIL are
activated with an anti-CD3 antibody in the presence of feeder cells and IL-2 and
expanded to high numbers over a 2 week period. Although the REP yields billions of
highly-differentiated cytolytic CD8+ T cells, the post-REP TIL exhibit a loss of
critical co-stimulatory molecules CD28 and CD27, are hyporesponsive to further
proliferative signals and are sensitive to activation-induced cell death (AICD) (90,
133). We do not have a state of the art standard protocol for expanding the TIL during
secondary expansion that will result in the optimal TIL necessary (mainly CD8+ T
cells) that will persist in the patient, while killing the tumor. We have previously
observed that CD8+ TIL that down-regulate CD28 have the capacity to up-regulate
alternative co-stimulatory molecules of the TNFR family, such as 4-1BB (90, 133).
We hypothesized that since the TIL expressed 4-1BB, the activation of the 4-1BB
co-stimulatory pathway would have an effect when added at the initiation of the TIL
REP. 4-1BB was activated using an agonistic anti-4-1BB antibody added during the
initiation of the TIL REP with anti-CD3 and the cells expanded with IL-2 for two
weeks. We found 4-1BB co-stimulation increased the CD8+ T-cell recovery and
significantly enhanced the anti-tumor killing activity of the TIL product. This was
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associated with increased expression of CTL-related factors, such as Granzyme B,
Perforin, and Eomes. However, this improved CTL phenotype was not associated
with KLRG1 expression and CD28 loss. TIL receiving 4-1BB co-stimulation during
the REP also had higher bcl-2 gene expression and increased resistance to apoptosis.
This was associated with longer persistence of the cells in vivo following adoptive
transfer into NOD/SCID γc-/- (NSG) mice. Our findings suggest that augmenting
TNFR co-stimulation through 4-1BB co-stimulation during melanoma TIL expansion
significantly improves the phenotype and function of tumor-reactive CD8+ CTL
without driving senescence and preserving certain memory T-cell properties. This
approach may greatly improve TIL persistence and anti-tumor activity in vivo after
adoptive transfer into patients

This Chapter is based upon and reprinted with permission from: Chacon JA, Wu
RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P,
Radvanyi L.PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031.
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4.2 Results
Induction of 4-1BB expression without induction of 4-1BB ligand after initiation
of the REP
We were first interested to determine whether 4-1BB is induced on CD8+ T cells
early during the REP and whether the PBMC feeder cells or the TIL themselves
express appreciable levels of the ligand for 4-1BB (4-1BBL) as a possible
endogenous source of 4-1BB co-stimulation for the CD8+ T cells.

For these

experiments TIL were labeled with CFSE to distinguish them from the feeder cells
before being activated by anti-CD3 in the REP. 4-1BB is up-regulated on T cells 2448 hours after activation. Thus, we analyzed CD8, 4-1BB and 4-1BBL expression on
the live TIL (CFSE+) and feeder cells (CFSE-) 1-2 days after REP initiation. Live
cells were gated and the CD8+CFSE+ population and the live CFSE- lymphocyte
population analyzed for 4-1BB and 4-1BBL expression. We found that in each case a
significant frequency of the CD8+ T cells in the TIL (40%-60%) had induced 4-1BB
expression relative to their corresponding pre-REP cells, while little or no 4-1BB
expression was found in the remaining live feeder cells (Figure 4.1A). However, no
appreciable 4-1BBL was expressed in either sub-population (Figure 4.1B). Thus,
CD8+ TIL induce 4-1BB expression after REP initiation, but little or no 4-1BBL is
expressed by either the TIL or the feeders.
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Figure 4.1. 4-1BB is expressed on CD8+ TIL within the first 2 days of REP
initiation. Pre-REP TIL were stained for the expression of CD8, 4-1BB, and 4-1BBL,
as shown. The REP was then set up with the TIL being labeled with CFSE prior to
being added to the flask for the TIL expansion in order to be able to distinguish the
TIL from excess of irradiated PBMC feeder cells added. On day 1 and day 2 of the
REP, the cells were harvested from the flasks and stained for the expression of CD3,
CD8, 4-1BB and 4-1BBL. For analysis of the TIL, the CFSE+ viable cells were gated,
and for the feeders, the CFSE- viable feeders were analyzed. We found that the TIL
up-regulated 4-1BB on the CD8+ subset, while the PBMC feeder cells had much less
4-1BB expression (A).

In contrast, both the CD8+ TIL and the PBMC feeders

expressed only low levels of 4-1BBL (B). No 4-1BBL expression was detected on the
CD4+ TIL on day 1 or day 2, or in the pre-REP cells (data not shown).
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Figure 4.1. 4-1BB is expressed on CD8+ TIL within the first 2 days of REP
initiation.

A)

B)
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Anti-4-1BB antibody increases CD8+ percentage and recovery during the REP
The results above indicate that although CD8+ TIL up-regulate 4-1BB expression,
there is no endogenous source of ligand activating 4-1BB co-stimulation. Thus, we
tested the effects of an exogenous source of ligand by adding an agonistic anti-4-1BB
mAb (BMS-663513) on the yield of CD8+ T cells during the REP. In the first set of
experiments we tested the effects of different concentrations of anti-4-1BB added on
day 0 (at the time of REP initiation). Addition of increasing concentrations of anti-41BB (0-1,000 ng/ml) resulted in an increasing frequency of CD8+ T cells with a
decrease in the percentage of CD4+ T cells, as shown in the flow cytometry dot plots
of two representative TIL lines (Figure 4.2A). This was manifested in an increased
yield of CD8+ T cells at the end of the REP (Figure 4.2B) with a maximum
frequency and yield of CD8+ T cells found at 500 ng/ml of mAb. Next, we
determined the optimal day of addition of anti-4-1BB to maximize the frequency and
yield of CD8+ T cells during the REP. Two TIL lines were tested by adding anti-41BB either on day 0, 1, 2, 3, or 5 of the REP. As shown in Figure 4.3, addition of the
mAb on day 0 was optimal in both TIL lines tested. Thus, in all subsequent
experiments anti-4-1BB was added at a dose of 500 ng/ml on day 0 of the REP. As a
control, we also tested the effects of an agonistic anti-CD28 mAb added to the REP at
this same dose in comparison to anti-4-1BB. CD28 is expressed on most pre-REP
CD4+ and CD8+ TIL . However, as opposed to anti-4-1BB, addition of an agonistic
anti-CD28 antibody did not increase the yield of CD8+ T cells (Figure 4.4).
In order to determine how reproducible the effects of 4-1BB co-stimulation
were, we performed experiments with TIL from 34 different patients. An equal
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number of pre-REP TIL from each patient (0.13 x 106 cells) were activated in a REP
with anti-4-1BB added on day 0 (“4-1BB REP”) or without anti-4-1BB (“Control
REP”) as control. As shown in Figure 4.5A, the anti-4-1BB REP significantly
increased the frequency of CD8+ T cells recovered after the REP. Comparison of the
yield and expansion of total CD8+ T cells for each TIL line also found a significant
increase with the addition of anti-4-1BB (Figure 4.5B and 4.5C). In contrast the
frequency and yield of CD4+ T cells exhibited an opposite trend (data not shown).
The stimulation of the 4-1BB pathway, however, did not alter the total T-cell yield
(Figure 4.5B right panel) or total TIL fold expansion (Figure 4.5C right panel).
Thus, 4-1BB co-stimulation at the initiation of the REP reproducibly increases the
frequency and yield of CD8+ T cells for adoptive cell therapy.

- 133 -

Figure 4.2. Addition of anti-4-1BB antibody to the REP increased the percentage
of CD8+ TIL. Anti-4-1BB antibody was added to the TIL on day 0 of the REP at the
indicated concentrations. All other conditions were the same in each culture. After 14
days the cells were harvested and stained for CD4 and CD8 expression and viable cell
counts were done using a hemocytometer following Trypan Blue staining. 4-1BB costimulation during the REP increased the frequency of CD8+ T cells in a dosedependent fashion in a representative TIL lines #2354 and #2199 (A). The total yield
of CD8+ T cells after the REP with different doses of anti-4-1BB is shown in two
independent TIL lines (#2354 and #2199) (B). A dose-dependent increase in CD8+
T-cell yield was noted, with 500ng/ml of anti-4-1BB antibody being optimal. The
results of triplicate cell counts ± standard deviation are shown.
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Figure 4.2. Addition of anti-4-1BB antibody to the REP increased the percentage
of CD8+ TIL.

A)

B)
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Figure 4.3. The optimal day to add the anti-4-1BB antibody was day 0 of the
REP for CD8+ TIL expansion. The TIL were subjected to the REP with or without
500 ng/ml of the anti-4-1BB antibody added on different days of the REP (Day 0, 1, 2,
3, or 5), as indicated. On day 14 of the REP, the post-REP TIL were analyzed for the
expression of CD8 on the viable population by flow cytometry. The highest increase
in CD8+ T-cell frequency was observed when anti-4-1BB antibody was added on day
0 of the REP (A). Addition of anti-4-1BB on Day 0 also resulted in the highest
change in the total yield of CD8+ T cells after the REP (B). The results shown are the
average of triplicate cell counts after the REP ± standard deviation. A two-way
ANOVA found that the Day 0 CD8+ T-cell count was significantly higher (p< 0.05)
than in the pre-REP TIL as well as for all other time points of anti-4-1BB addition (B).
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Figure 4.3. The optimal day to add the anti-4-1BB antibody was day 0 of the
REP for CD8+ TIL expansion.

A)

B)
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Figure 4.4. Comparison of the addition of agonistic anti-4-1BB and agonistic
anti-CD28 to the TIL REP. Melanoma TIL from 2 patients were subjected to the
REP with or without addition of anti-4-1BB (500 ng/ml) or anti-CD28 (500 ng/ml)
added during the REP initiation. Post-REP TIL were harvested, counted, and stained
for the expression of CD8, CD27, and CD28. Gating was done on the viable cells.
Addition of anti-4-1BB antibody increased the yield of CD8+ T cells over the control
(IL-2) REP significantly more than addition of anti-CD28. An average of 3
independent cell counts are shown with bars indicating standard deviation. Statistical
analysis was done using a two-way ANOVA with Bonferroni post-tests. An asterisk
above the bar indicates a p-value of <0.05 relative to the control (IL-2) REP. In each
case anti-4-1BB induced a significant increase in CD8+ T-cell yield over anti-CD28.
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Figure 4.4. Comparison of the addition of agonistic anti-4-1BB and agonistic
anti-CD28 to the TIL REP.
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Figure 4.5. Addition of 4-1BB antibody in the REP increases CD8+ T-cell
frequency and yield in a large cohort of patient samples (n= 34). The effects of
addition of an optimal dose of anti-4-1BB (500 ng/ml), as determined previously,
were tested in rapid expansions of TIL from 34 separate patient tumors. Addition of
anti-4-1BB significantly increased the frequency of CD8+ T cells in the final TIL
product in the patient population (A). CD8+ T-cell yield (B), and the fold expansion
of CD8+ cells (C), was significantly increased when anti-4-1BB was added to the
REP over the patient population. However, 4-1BB stimulation did not alter the total
T-cell yield (B) or the total TIL fold expansion (C). Statistical analysis was done
using the Wilcoxon signed rank test using biological relevance occurring when p<
0.05.

- 140 -

Figure 4.5. Addition of 4-1BB antibody in the REP increases CD8+ T-cell
frequency and yield in a large cohort of patient samples (n= 34).

A)

B)

C)
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4-1BB co-stimulation during the REP does not restrict the TCR Vβ repertoire.
We wanted to address the possibility that although 4-1BB co-stimulation enhances
the outgrowth of CD8+ T cells during the REP, it may lead to an oligoclonal
expansion of certain CD8+ T-cell clones restricting the CD8+ T-cell repertoire after
the REP. To test this, we sorted CD8+ T cells after rapid expansion with or without
anti-4-1BB from 2 independent patient samples and performed Vβ spectratyping on
isolated RNA. Analysis of the number of detected major Vβ subtypes and the number
of CDR3 region lengths in each represented Vβ family revealed that, although some
random gains and losses of Vβ CDR3 peaks occurred in either situation, the TCR
repertoire of the 4-1BB-costimulated post-REP CD8+ T cells remained as diverse as
in REPs that did not receive 4-1BB co-stimulation with no evident skewing towards
any specific Vβ family evident (Figure 4.6).
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Figure 4.6. TCR Vβ repertoire is not restricted in the post-REP TIL that
received 4-1BB co-stimulation. RNA was isolated from pre-REP TIL. These TIL
then underwent the REP with or without the addition of the anti-4-1BB antibody.
RNA was isolated on the post-REP TIL and Vβ spectratyping analysis was done on
pre-REP and the post-REP TIL. In 2 representative TIL lines 2549 and 2550, we
found that the TIL isolated from the IL-2 or IL-2+4-1BB REP retained a diverse TCR
Vβ repertoire without any increased oligoclonality.
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Figure 4.6. TCR Vβ repertoire is not restricted in the post-REP TIL that
received 4-1BB co-stimulation.
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TCR V family

4-1BB co-stimulation during the REP preserves CD28 expression in CD8+ T cells
We have previously reported that many CD8+ TIL down-regulate CD28 expression
after the REP and that these cells became hyporesponsive to re-stimulation with
melanoma antigens such as MART-1 and were more susceptible to cell death. The
remaining CD8+CD28+ T cells had a superior survival and responsiveness to
antigenic re-stimulation. Preservation of CD28 expression was also previously shown
to be associated with longer telomere length and in vivo persistence of transferred TIL.
CD27 is another effector-memory marker that can be down-modulated. Studies at the
National Cancer Institute (Bethesda, MD) have demonstrated that in melanoma
patients receiving ACT, the total number of CD8+CD27+ TIL administered to patients
was associated with improved clinical responses. Thus, we went on to investigate the
effects of the anti-4-1BB mAb in modulating both the extent of CD28 and CD27
expression.
An example of the flow cytometry analysis of one TIL line is shown in Figure
3A and 3C. A significant loss of surface CD28 expression occured in the CD8+ TIL
subset during the Control REP, while in the 4-1BB REP the frequency of CD28+ cells
in the CD8+ subset remained stable (Figure 4.7A). In contrast, levels of CD27
expression did not decrease during the Control REP relative to pre-REP levels and
anti-4-1BB did not appreciably alter CD27 expression (Figure 4.7C). In order to
confirm these results, we analyzed the 34 separate patient TIL lines used previously
for changes in CD28 and CD27 frequency and fold expansion in the CD8+ TIL subset
(Figure 4.7B and D). Plotting the pre-REP, Control REP and 4-1BB REP found that
the frequency of CD28+ TIL significantly decreased from an average of around 50%
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to 30% over the entire TIL sample set, a situation that was mostly reversed when anti4-1BB was added to the REP (Figure 4.7B). The left hand graph in Figure 4.7B
shows that this preservation of CD28 expression was not driven by a few lines that
highly increased CD28 expression during the 4-1BB REP, but that in most individual
TIL lines a loss of CD28 occurred that was regained with anti-4-1BB , as seen by the
“V-shaped” pattern. As before, CD27 frequency levels and fold change over the 34
TIL lines tested was not significantly changed during either the Control or the 4-1BB
REP from pre-REP levels in the CD8+ TIL subset (Figure 4.7D).
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Figure 4.7. Addition of anti-4-1BB antibody maintained CD28 expression on
CD8+ T cells during the REP in a large cohort of patient samples (n= 34). TIL
from a representative patient was subjected to the REP with or without the addition of
anti-4-1BB antibody and the cells stained for CD8 and CD28 (A) or CD8 and CD27
(B) and analyzed by flow cytometry both before the REP (pre-REP) and after the
control (IL-2) REP or REP with anti-4-1BB (IL-2+4-1BB). Viable cells were gated
and the frequency of CD28+ (A) or CD27+ (C) in the CD8+ subset analyzed. The
change in CD28 or CD27 expression in the CD8 + T-cell subset during the REP with
or without added anti-4-1BB was determined in 34 independent TIL lines (B and D).
The left hand panels in B and D show the overall median difference in the frequency
of CD28+ or CD27+ cells in the CD8+ subset over the entire patient population. The
right hand panels in B and D show the fold expansions in the CD28+ or CD27+
populations. Statistical analysis was done using Wilcoxon signed rank sum test using
biological relevance occurring when p< 0.05.
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Figure 4.7. Addition of anti-4-1BB antibody maintained CD28 expression on
CD8+ T cells during the REP in a large cohort of patient samples (n= 34).

A)

C)

B)

D)
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Addition of 4-1BB antibody to the REP increases CD8+ effector phenotype.
A number of hallmarks are used to differentiate CD8+ T cells that gain effective
cytotoxic T lymphocyte (CTL) or killing function.

These include the gain in

intracellular expression of cytolytic granule molecules, such as perforin (Perf) and
granzyme B (GB).

Increased expression of the T-box transcription factor

eomesodermin (Eomes), helping drive Perf expression, can also be seen . In some
cases, later stage or more highly differentiated effector CD8+ T cells gain expression
of an NK marker called killer cell lectin like receptor subfamily G member 1 (KLRG1), a marker usually associated with senescent, end-stage CD8+ T cells with low
proliferative capacity. Using flow cytometry analysis as before, we analyzed changes
in Perf, GB, Eomes, and KLRG-1 expression in the CD8+ TIL subset. Perf changes
were monitored in the 34 separate patient TIL lines, while GB was determined in a
subset of 17 of these lines (Figure 4.8B and D). While both Perf and GB frequencies
increased during the REP, addition of anti-4-1BB induced significantly higher
frequency of Perf and GB CD8+ T cells (Figure 4.8A and C). Eomesodermin and
KLRG-1 expression changes were studied in 10 different TIL lines. No significant
differences however were found between the Control REP and 4-1BB REP in each
case, although Eomes did show a tendency to increase at variable levels in many of
the TIL lines (Figure 4.9).
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Figure 4.8. Addition of anti-4-1BB antibody increased Granzyme B (GB) and
Perforin (Perf) expression in CD8+ T cells during the REP in multiple patient
samples. TIL from a representative patient was subjected to the REP with or without
the addition of anti-4-1BB antibody and the cells stained for CD8 and Perf (A) or
CD8 and GB (B) and analyzed by flow cytometry both before the REP (pre-REP) and
after the control (IL-2) REP or REP with anti-4-1BB (IL-2+4-1BB). Viable cells
were gated and the frequency of Perf+ (A) or GB+ (C) in the CD8+ subset analyzed.
The change in Perf or GB expression in the CD8 + T-cell subset during the REP with
or without added anti-4-1BB was determined in larger cohort of patients TIL samples
(B and D). 4-1BB co-stimulation during the REP significantly increased Perf
expression in CD8+ T cells in 34 separate TIL line tested (B) and increased GB
expression in 11 separate TIL lines tested (D). Statistical analysis was done using
Wilcoxon signed rank sum test using biological relevance occurring when p< 0.05.
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Figure 4.8. Addition of anti-4-1BB antibody increased Granzyme B (GB) and
Perforin (Perf) expression in CD8+ T cells during the REP in multiple patient
samples.

A)

B)

C)

D)

- 151 -

Figure 4.9. Increased expression of Eomes in TIL isolated after the REP with
anti-4-1BB antibody, with no significant change of KLRG-1 expression. The TIL
subjected to the REP with or without the anti-4-1BB antibody were stained for CD8
and the expression of T-box transcription factor Eomes (A) and Killer cell lectin like
receptor subfamily G member 1 (KLRG1) (B). 4-1BB co-stimulation during the REP
led to an increase in Eomes+ (A) in the CD8+ population (n=21). However, there was
no difference in expression of KLRG-1 (B) in the CD8+ population (n=11). Statistical
analysis was done using the Wilcoxon signed rank test with biological relevance
occurring when p< 0.05.
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Figure 4.9. Increased expression of Eomes in TIL isolated after the REP with
anti-4-1BB antibody, with no significant change of KLRG-1 expression.

A)

B)
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Analysis of cytokine secretion and anti-tumor CTL activity.
The TIL REP generates CD8+ T cells with increased effector function. We
determined the effector activity of the TIL by testing their ability to produce
cytokines in response to TCR stimulation post-REP and their ability to kill tumor
cells or targets pulsed with melanoma antigen peptides. As before, TIL from different
patient pre-REP lines were rapidly expanded with or without added anti-4-1BB
antibody. The post-REP TIL were then sorted by FACS to isolate the CD8+ subset,
washed, and rested for 5-6 h, and then assayed for cytokine production or CTL
activity. As shown in Figure 4.10, sorted CD8+ T cells from REP cultures including
anti-4-1BB secreted significantly higher amounts of

IFN-γ, TNF-α, and IL-2

following CD3 activation. CTL activity was determined using a previoulsy published
assay measuring capsase 3 cleavage in target cells by flow cytometry. Figure 4.11
shows the results of post-REP CTL assays on three different HLA-A0201+ patient
TIL lines using an HLA-A0201-matched melanoma cell line target (cell line 624) and
an HLA-A-unmatched melanoma target (cell line 938), or T2 target cells pulsed with
a an HLA-A0201 MART-1 peptide epitope. We found that the sorted CD8+ T cells
from the anti-4-1BB-treated REP cultures had higher levels of specific killing activity
than cells from control REP cultures (Figure 4.11). Levels of non-specific killing
were low in all cases (Figure 4.11). Staining with an HLA-A0201 MART-1 peptide
HLA tetramer found that the frequency of MART-1-specific cells in was only slightly
higher in the post-REP TIL from the 4-1BB costimulate expansions (Figure 4.12)
suggesting that the enhanced killing activity (at least in the case of MART-1 antigen)
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is not due to a higher frequency of melanoma antigen-specific CD8+ T cells after the
REP with anti-4-1BB.
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Figure 4.10. TIL isolated after rapid expansion with anti-4-1BB antibody
displayed an increased ability to secrete IFN-γ, TNF-α, and IL-2 after TCR restimulation. Melanoma TIL rapidly expanded with or without the addition of the
anti-4-1BB antibody were re-stimulated with anti-CD3 antibody in 96-well plates.
Culture supernatants were collected after 24 hours and assayed using anti-cytokine
beads for IFN-γ, TNF-α, and IL-2 using a Luminex-100 system. Results from 3
different TIL lines comparing the control (IL-2) group with the IL-2+4-1BB group
are shown for IFN-γ (A) TNF-α (B), and IL-2 (C). In each case the net production of
the cytokines was calculated by subtracting the control wells (no anti-CD3) from the
wells that had anti-CD3. The averages and standard deviation of triplicate wells are
shown in each case. A paired student’s t-test was used to determine statistical
significance between groups with p< 0.05 indicating statistical significance.
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Figure 4.10. TIL isolated after rapid expansion with anti-4-1BB antibody
displayed an increased ability to secrete IFN-γ, TNF-α, and IL-2 after TCR restimulation.

A)

B)

C)
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Figure 4.11. Addition of anti-4-1BB antibody to the REP led to increased postREP TIL tumor-specific CTL activity. Melanoma TIL from HLA-A0201+ patients
with a significant population of CD8+MART-1 tetramer+ cells were rapidly expanded
with or without anti-4-1BB as before. The post-REP TIL were sorted by FACS for
CD8+ T cells and assayed for tumor antigen-specific CTL activity using a flowcytometry-based assay that measures caspase-3 cleavage in target cells. The results
of three different patient TIL lines are shown. The top panels (A) show the CTL
activity of TIL #2292 using the melanoma cell line 624 (HLA-A0201+) and the
control HLA-A-unmatched line 938 as targets (left side), or MART-1 peptide-pulsed
T2 target cells as targets (right side). The bottom panels (B) show the CTL activity of
two other HLA-A0201+ TIL lines (#2276 and #2122) against 624 or 938 cells with
similar results. In all cases (A and B) the levels of non-specific killing were markedly
lower.
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Figure 4.11. Addition of anti-4-1BB antibody to the REP led to increased postREP TIL tumor-specific CTL activity.

A)

B)

C)
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Figure 4.12. 4-1BB stimulation does not increase the frequency of MART-1specific cells. TIL were expanded with or without the anti-4-1BB antibody. Post-REP
TIL were stained for CD8 and MART-1 tetramer using flow cytometry. The TIL were
gated on the live population and analysis of the both types of post-REP TIL found
that the percentage of CD8+ MART-1-specific cells was similar in 3 representative
TIL lines
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Figure 4.12. 4-1BB stimulation does not increase the frequency of MART-1specific cells.
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Increased bcl-2 expression and post-REP cell survival in TIL rapidly expanded
with 4-1BB co-stimulation.
4-1BB has been shown to prevent apoptosis by up-regulating anti-apoptotic
molecules, such as bcl-xL and bcl-2 . We have previously shown that 4-1BB protects
post-REP TIL from activation-induced cell death . Therefore, we wanted to determine
whether the addition of anti-4-1BB during the REP resulted in any change in
expression of the major bcl-2 family members that are anti-apoptotic (bcl-2 and bclxL) or pro-apoptotic (bim). We also looked at the levels of survivin, a member of the
inhibitor of apoptosis family that has also been shown to be induced by TNF-R family
signaling, such as OX40 . Post-REP TIL from two patients were isolated as before
and subjected to real-time quantitiative PCR analysis. Interestingly, bcl-2 and not
bcl-xL was consistently up-regulated in TIL that received 4-1BB co-stimulation
during the REP, while bim was not altered significantly (Figure 4.13A). We also
found a significantly higher expression of the Survivin gene in the 4-1BB
costimulated TIL, although this was more nominal than with bcl-2 (Figure 4.13A).
We also confirmed the increased expression of bcl-2 using flow cytometry. We
found an increased expression in the bcl-2 mean fluorescence intensity (MFI) in TIL
isolated from the 4-1BB REP compared to the control REP (IL-2) (Figure 4.13B).
We also analyzed the cell survival ability of post-REP TIL when re-cultured without
cytokine or with added IL-2 for 5 days by determining the recovery of viable CD8+
cells and their level of apoptosis. IL-2 therapy is given immediately after TIL
adoptive transfer into patients and, thus, we were interested in how the cells respond
to IL-2 following the REP. The cells were harvested and washed three times to
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remove any remaining cytokine in the REP and replated. Remarkably, CD8+ TIL
from both patients that received 4-1BB co-stimulation during the REP exhibited a 34- fold increase in cell number with or without added IL-2 (200 IU/ml), while control
REP CD8+ TIL only further expanded with additional IL-2 and had a reduction in the
number of cells when no exogenous IL-2 was provided (Figure 4.13C). This
improved yield of TIL from 4-1BB REP cultures when post-REP cells were re-plated
with or without added IL-2 was also reflected in a lower percentage of apoptotic
(Annexin V+) cells (Figure 4.13D). Although the data from the four separate TIL
lines were not statistically significant due to the different intrinsic apoptosis
sensitivities of each line, there was a clear trend towards a decrease in Annexin V+
cells in each case with TIL from the 4-1BB REP cultures (IL-2+4-1BB) versus
control REP cultures (IL-2) when the post-REP cells were re-plated without IL-2 or
with added IL-2 (Figure 4.13D).

\
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Figure 4.13. Increased expression of anti-apoptotic molecules and improved
survival in post-REP TIL that received 4-1BB co-stimulation during the REP.
RNA from post-REP TIL that were rapidly expanded with or without anti-4-1BB
were subjected to quantitative real-time PCR (qRT-PCR) analysis for bcl-2, bcl-xL,
bim, and survivin (A). The results of two representative patient TIL lines are shown
(#2392 and #2396). Each PCR reaction was ran in triplicate with a CV of <5% for all
assays. The results with the IL-2+4-1BB REP were normalized against the levels of
gene expression in the control (IL-2) REP, as indicated with the 1-fold expression for
the control REP for each gene. The increase in bcl-2 expression in the IL-2+4-1BB
group was confirmed in three different TIL samples by intracellular staining for bcl-2
using flow cytometry (B). The post-REP TIL were also analyzed for their ability to
survive and further expand when re-cultured with or without IL-2 (100 U/ml) for 5
days, as described in the Materials and Methods (C and D). Viable cell counts
together with flow cytometry analysis for CD8 expression was performed to calculate
the fold change in CD8+ T cells after the re-culturing period (C). TIL from 4-1BB
REP (IL-2+4-1BB) or control REP (IL-2) cultures from 4 different patients were also
subjected to staining with Annexin V and 7-AAD after re-plating without or with 200
IU/ml IL-2 for 5 days and the frequency of Annexin V+ 7-AAD- (apoptotic cells)
were determined (D).
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Figure 4.13. Increased expression of anti-apoptotic molecules and improved
survival in post-REP TIL that received 4-1BB co-stimulation during the REP.
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B)

C)

D)
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4-1BB co-stimulation during the REP enhances responsiveness of MART-1
specific TIL to antigen re-stimulation.
Previously, we reported that MART-1-specific CD8+ T cells that lose CD28 become
hypo-responsive to antigenic re-stimulation by peptide-pulsed DC following the REP.
We were therefore interested in whether additional 4-1BB co-stimulation during the
REP yields more CD8+ T cells that may be more responsive to antigenic restimulation following the REP. CD8+ TIL from HLA-A0201+ patients that had a
significant population of MART-1 peptide tetramer+ CD8+ T cells were rapidly
expanded with or without 4-1BB co-stimulation. Similar starting numbers of CD8+
MART-1 tetramer+ TIL were used (data not shown). The cells were labeled with
eFluor670 dye and re-stimulated with HLA-A0201+ MART-1 peptide-pulsed DC, as
previously described

and cell counts were done using trypan blue and a

hemocytometer. As shown in Figure 4.14A, CD8+ TIL isolated from 4-1BB costimulated REP cultures had an enhanced response to MART-1 peptide re-stimulation,
as shown by the increased number of cell divisions measured by eFluor670 dilution in
the CD8+ MART-1 tetramer+ gated cells (Figure 4.14A). Figure 4.14B shows the
results of two experiments with HLA-A0201+ post-REP TIL re-stimulated with HLAA0201+ MART-1 peptide-pulsed DC.

In both cases, the fold increase in gated

CD8+MART-1 tetramer+ cells was significantly higher in the samples that originally
received anti-4-1BB in the REP (IL-2+4-1BB).
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Figure 4.14. CD8+ MART-1-reactive TIL provided 4-1BB co-stimulation during
the REP have a greater proliferative response to re-stimulation with MART-1
peptide. TIL from HLA-A0201+ patients were rapidly expanded with or without
added anti-4-1BB antibody. The cells were labeled with eFluor670 dye and restimulated with HLA-A0201+ MART-1 peptide-pulsed DC, as previously described .
The post-REP TIL were labeled with the cell division dye eFluor670 (Invitrogen) and
re-stimulated with HLA-A0201-matched mature DC pulsed with MART-1 peptide
for 7 days. The cells were harvested and stained for CD8 and MART-1 tetramer and
analyzed by flow cytometry for the frequency of divided (eFluor670 low) in the gated
CD8+ MART-1 tetramer+ subset. One representative experiment out of two is shown.
As shown in A, CD8+ TIL isolated from 4-1BB costimulated REP cultures (#2183)
had an enhanced response to MART-1 peptide re-stimulation, as shown by the
increased number of cell divisions measured by eFluor670 dilution in the CD8+
MART-1 tetramer+ gated cells. TIL isolated from REP cultures that received anti-41BB also exhibited an increase in the fold expansion of CD8+ MART-1 tetramer+
cells following re-stimulation of the post-REP TIL with MART-1 peptide pulsed DC
as shown in experiments with two separate TIL lines (#2183 and #2559) (B).
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Figure 4.14. CD8+ MART-1-reactive TIL provided 4-1BB co-stimulation during
the REP have a greater proliferative response to re-stimulation with MART-1
peptide.

A)

B)
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Determining the role of post-REP TIL expanded with or without anti-4-1BB
using NSG mice.
We next wanted to investigate the role of the TIL expanded with anti-4-1BB antibody
using an in vivo mouse model. We chose to use the NOD scid IL2 receptor gamma
chain knockout mice (NSG) mice because these mice do not have T cells, B cells, or
NK cells and can be used as a host for transferred human cells without inducing
rejection to the transferred cells. We expanded the TIL with or without anti-4-1BB
antibody for 2 weeks. During the 2 week period, we harvested the human melanoma
cell line WM35, which is an amelanotic line that is derived from radial growth phase
and is an A2+ cell line. We injected 2x106 WM35 cells subcutaneously into the mice.
After 1 week, 25x106 post-REP TIL were injected intravenously through the tail vein
of the mice. IL-2 was given to the mice through intraperitoneal injections of 20,00025,000 IU, 2 times per day on days 0-3 to help the transferred T cells persist. We
conducted 2 independent experiments using different post-Rep TIL lines. For our first
experiment, we found that the post-REP TIL that were expanded with the anti-4-1BB
antibody exhibited an increase in CD45+ cells (leukocytes), and particularly CD3+
CD8+ T cells in the lung, blood, and spleen (Figure 4.15). The tumor size also
decreased in size when the mice were injected with the post-REP TIL that were
expanded with the anti-4-1BB antibody (Figure 4.16).
In our second mouse study, we used the same strain of mice (NSG) and
melanoma tumor cell line (WM35), but a different post-REP TIL line, This time, the
TIL line was 2559 as compared to TIL 2533 that was used in our first experiment. We
injected the melanoma cell line subcutaneously into the mice. During this time, the
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TIL were being expanded with or without the anti-4-1BB antibody. The post-REP
TIL were subsequently injected I.V. into the mice and IL-2 was given. As we saw
before, the post-REP TIL expanded with the anti-4-1BB antibody during the REP
exhibited better persistence than the post-REP TIL expanded with IL-2 alone (Figure
4.17). When we measured the tumor size on different days, we observed that the mice
that received the TIL expanded with anti-4-1BB antibody clearly had tumor
regression, compared to the mice who received TIL expanded in IL-2 alone (Figure
4.18).
Our data suggests that not only are we able to expand a better TIL product
with increased CD8+, with increased CTL function and phenotype, but we are also
able to produce TIL that are able to persist in vivo using the NSG mouse model and
subsequently kill the tumor.

- 170 -

Figure 4.15. Persistence of TIL in vivo using an NSG mouse model. Using an NSG
mouse model, we injected human melanoma cell line WM35 into the mice. During
this time the TIL were undergoing the REP with or without the addition of anti-41BB antibody. After 1 week of the melanoma cell line being injected into the mice,
the post-REP TIL that were expanded with or without anti-4-1BB antibody were
subsequently injected. Over a period of 7 days, any tumor change was measured
using calipers. On day 7, the mice were sacrificed and the TIL persistence was
measured in various organs and the blood. We found that in the blood, lung, and
spleen, the post-REP, particularly the CD3+ CD8+ that were expanded with anti-41BB antibody exhibited better persistence than the post-REP expanded with IL-2
alone.
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Figure 4.15. Persistence of TIL in vivo using an NSG mouse model.
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N=4

Figure 4.16. Reduced tumor size in NSG mice when injected with TIL expanded
with IL-2+anti-4-1BB antibody. The NSG mice were injected with the human
melanoma cell line WM35. After 1 week, post-REP TIL expanded with or without
the anti-4-1BB antibody were injected into the tumor bearing mice. On day 7 of the
TIL injection, the tumor size was measured and the mice were sacrificed to measure
persistence of the TIL in different organs and in the blood. We found that the mice
that received the post-REP TIL expanded with the anti-4-1BB antibody exhibited
better tumor regression than the mice that were injected with our control TIL.
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Figure 4.16. Reduced tumor size in NSG mice when injected with TIL expanded
with IL-2+anti-4-1BB antibody.
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Figure 4.17. TIL expanded with IL-2+anti-4-1BB antibody persist better in vivo
than TIL grown in IL-2 alone. In our second in vivo experiment, we used the TIL
line 2559. The mice were challenged with the human melanoma cell line WM35.
After 1 week, the post-REP TIL 2559 that were expanded with or without the anti-41BB antibody were injected into the mice. The tumor burden was measured over a
period of 1 week. After 1 week, the mice were sacrificed. We found that in the spleen
of the mice, the post-REP TIL that were expanded with anti-4-1BB antibody were
persisting better than the control TIL.
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Figure 4.17. TIL expanded with IL-2+anti-4-1BB antibody persist better in vivo
than TIL grown in IL-2 alone.
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Figure 4.18. TIL expanded with the anti-4-1BB antibody induce tumor
regression. The NSG mice were challenged with a human melanoma cell line WM35.
After 1 week, post-REP TIL that were expanded with or without anti-4-1BB antibody
were injected into the mice. Over 1 7 day period, the tumor size was measured using
calipers. We observed that the mice that received the post-REP TIL expanded with
IL-2 alone did not exhibit a decrease in tumor size over the 7 day period. However,
the mice that received the post-REP TIL that were expanded with anti-4-1BB
antibody exhibited tumor regression.
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Figure 4.18. TIL expanded with the anti-4-1BB antibody induce tumor
regression.
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4.3 Discussion
Although adoptive T-cell therapy (ACT) is the most effective therapy for late
stage metastatic melanoma patients that have other first and second line therapies,
there are still improvements to be made to the therapy. The current therapy does not
preferentially expand TIL that will be able to persist and induce a long-term tumor
regression in vivo. The current protocol expands billions of TIL during the REP, but
the final TIL product that is infused may be sub-optimal to treat all patients. We have
found that the more CD8+ TIL infused, the better clinical responses patients have (38).
However, the post-REP TIL lose critical co-stimulatory molecules such as CD27 and
CD28 (90, 133). The post-REP TIL are also susceptible to AICD and hyporesponsive to antigenic re-stimulation (90, 133). Although other co-stimulatory
molecules, such as those from the TNFR super family, have been demonstrated to
increased CTL activity in CD8+ T cells, the role of these molecules, such as 4-1BB
and OX40 have never been studied in expanding TIL from metastatic melanoma
patients.
We have previously demonstrated that pre- and post-REP TIL express 4-1BB
and OX40. 4-1BB was preferentially expressed in the CD8+ subset, whereas OX40
was preferentially expressed in the CD4+ subset (90). Therefore, we wanted to
investigate what role activating the 4-1BB pathway would have during the secondary
expansion of the TIL. Overall, our data demonstrates that activating the 4-1BB
pathway during the REP expands the CD8+ population that contain an increased
cytolytic phenotype and function. In addition the TIL expanded with the anti-4-1BB
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antibody exhibited an increase in the level of the anti-apoptotic molecule bcl-2 and
appeared to persist more in the NSG mouse model.
We would also like to investigate the role of OX40 in expanding the TIL
during the REP since it is also expressed on the TIL. Preliminary studies done in our
lab suggest that using an agonistic anti-OX40 antibody preferentially expands the
CD4+ TIL. The specific role of CD4+ TIL used for ACT for melanoma patients has
yet been to be determined and needs to be further investigated.
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CHAPTER 5: OVERALL DISCUSSION AND FUTURE DIRECTIONS
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5.1 Overall Discussion
Avoiding immune destruction has recently been pioneered as a hallmark of
cancer (134). New approaches augmenting the immune system have recently been
utilized to treat cancer. Immunotherapy uses the patient’s immune system to treat
their malignant disease. In the last few years, the FDA approved 2 new drugs for the
treatment of melanoma (135, 136). One of the drugs, ipilumamab (anti-CTLA-4)
specifically modulates the immune system to treat melanoma patients (136). AntiCTLA-4 specifically blocks the CTLA-4 molecule that inhibits T-cell activation,
allowing co-stimulation through CD28 and CD80/86 to occur, inducing T-cell
proliferation and survival (136). Using this approach led to an insight into using
antibodies to modulate the immune system. In our study, we wanted to investigate an
approach using an agonistic antibody to stimulate T-cell responses. 41BB was first
discovered in the 1980s and has since been demonstrated to induce effector CD8+
CTL that induce anti-viral and anti-tumor responses (87, 89, 93-95). In 2008, 4-1BB
was found to be in the top 20 agents to impact cancer research (137). Since we found
that 4-1BB was expressed on freshly isolated CD8+ cells, we wanted to investigate
whether activating the 4-1BB pathway using an agonistic anti-4-1BB antibody would
affect our TIL cultures. Although using ACT with TIL has resulted in a 50% response
rate for treating metastatic melanoma patients, we believe that by modifying the way
we expand the TIL, we can make an impact on the overall therapy.
By activating the 41BB pathway using an agonistic anti-41BB antibody
during the initial TIL isolation, we observed that the TIL were proliferating better,
and expanding CD8+ CTL that exhibited more Granzyme B and IFN-gamma
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secretion in comparison to expanding the TIL with IL-2 alone. Activating the 4-1BB
pathway increased the number of patients that would be eligible for secondary
expansion in just 3 weeks compared to the 4-5 weeks that is traditional needed to
initially expand the TIL.
Although our initial finding could potentially impact the amount of patients
eligible for secondary expansion and decrease the culture period for the initial
isolation and expansion of the TIL, we wanted to investigate the possible mechanism
behind our findings. Our initial observations were found by using TIL isolated and
expanded from the melanoma tumor fragment. However, another approach used to
isolate TIL from the melanoma tumor uses enzymes to digest the tumor, followed by
Ficoll to separate the TIL into a single layer. This approach is useful in preventing
any negative suppressor cells or factors that may impact the expansion of the TIL.
However, using this approach does not always result in expanding the TIL to the 506
needed to undergo the secondary expansion and we have found to have better success
in expanding TIL by setting up multiple fragments from the melanoma tumor instead.
When we set up parallel experiments using the enzymatic digest alongside the
fragment set up, we found that activating the 4-1BB pathway expanded the TIL more
than the traditional IL-2 when we expanded the TIL from the melanoma fragments.
We found no difference when we expanded the TIL from the enzymatic digest with or
without 4-1BB ligation. This prompted us to investigate the possible mechanism
behind this observation.
As mentioned earlier, the major difference between using the enzymatic
digestion method and the fragment set up is that enzymatic digestion method
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physically separates the TIL from the rest of the cells within the tumor, compared to
the fragment set up that allows the TIL to be in contact with other cells within the
microenvironment. We hypothesized that 4-1BB ligation during the initial TIL
isolation from the melanoma fragment activates not only the T cells, but other cells
within the microenvironment. 4-1BB is expressed on a number of cells, such as T
cells, NK cells, B cells, and dendritic cells. When we investigated if activating the 41BB pathway augmented the other cells in the microenvironment, we found that 41BB was indeed expressed on the dendritic cells within the melanoma fragment and
activating the 4-1BB pathway increased activation markers on the dendritic cells. The
dendritic cells also exhibited increased secretion and expression of IL-6 and TNFalpha. We hypothesized that the T cells within the fragment were becoming activated
either directly through the TCR or indirectly by cytokines secreted by other cells
(dendritic cells). When we blocked the MHC class I, we found a significant decrease
in expansion of CD8+ T cells that migrated out of the melanoma fragment compared
to when we did not block the MHC class I. Our findings indicated that the addition of
the anti-4-1BB antibody is activating the dendritic cells and the T cells, resulting in
the T cells becoming more activated, proliferating more and migrating out of the
tumor at a faster rate. Providing dendritic cells co-stimulation using an anti-4-1BB
antibody has resulted in inducing their survival through increased pro-survival
molecules, such as bcl-2 and bcl-xL. There are a number of factors to consider about
the activation of the dendritic cells by the 4-1BB ligation. One point to consider is
that the level of initial activation differs from dendritic cell to dendritic cell and from
area to area of the tumor fragment. We cut the melanoma tumor into multiple
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fragments, but each fragment can be independent of the other fragment, depending on
the cells within the microenvironment. The levels of surface expression of 4-1BB and
subsequent activation from the 4-1BB ligation may differ, depending what cells are
within the environment. Nevertheless, we have found that the dendritic cells within
the tumor microenvironment do express different levels of 4-1BB and become more
activated with 4-1BB ligation.
When we added the anti-4-1BB antibody to the TIL undergoing the secondary
expansion (REP), we preferentially expanded the CD8+ TIL that demonstrated an
enhanced effector phenotype and function. In addition, when we injected the postREP TIL into an NSG mouse, we found that the TIL expanded with the anti-4-1BB
antibody persisted longer and induced an anti-tumor effect. This data shows promise
of using the anti-4-1BB antibody to expand CD8+ TIL during the REP. We have
previously demonstrated that the more CD8+ TIL infused in the patient, the better
clinical response the patients undergo. However, the current REP protocol does not
utilize methods to preferentially expand more CD8+ than CD4+ TIL and most of the
time, the CD4+ TIL outgrow the CD8+ population during the REP.
Overall, we believe that utilizing an agonistic anti-4-1BB antibody to provide
co-stimulation to the TIL during the different stages of the ACT can provide a better
TIL product (Figure 5.1). We can add the anti-4-1BB antibody to the fragments
during the initial TIL isolation and expansion. We have demonstrated that by doing
this, we not only activate the TIL, but also the dendritic cells that are in the
microenvironment that could then directly (through TCR) or indirectly (cytokines)
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activate the TIL. Subsequently, the 4-1BB activation will induce the CD8+ TIL to
proliferate and migrate out of the fragment and induce translocation of NFκB.
During the REP, as mentioned previously, the CD4+ TIL can outgrow the
CD8+ TIL. We would like to infuse mainly CD8+ TIL since this is the population that
has been shown to induce clinical responses in melanoma patients undergoing ACT
using TIL. When we added the anti-4-1BB antibody during the secondary expansion
phase we found that the 4-1BB ligation increased the expansion of the CD8+ TIL,
increased the effector phenotype and function, and increased the anti-apoptotic
molecule bcl-2. 4-1BB activation during the TIL expansion also maintained the
expression of a critical co-stimulatory molecule CD28, that is normally downregulated after the REP. We previously found that CD28- post-REP TIL are hyporesponsive to antigenic stimulation and susceptible to AICD (90, 133).
We believe these qualities (improved effector phenotype, function, and
maintenance of CD28 expression, and increased anti-apoptotic molecule bcl-2, would
produce a TIL product that is able to persist in vivo and maintain tumor control
(Figure 5.1).
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Figure 5.1. Proposed model for the role of 4-1BB co-stimulation during TIL
expansion and TIL therapy in vivo. The schematic shows the different stage of TIL
expansion through therapy starting from the initial expansion from tumor fragments
(pre-REP stage) followed by the REP (rapid expansion) stage generating the final
infusion product. Past expansion protocols have not provided enough co-stimulation
to CD8+ TIL, especially through 4-1BB, critical at this stage of effector-memory
differentiation. We have found that providing 4-1BB co-stimulation during the REP
improves the expansion of tumor-reactive CD8+ T cells that maintain CD28
expression and up-regulate cell survival molecules that are more responsive to
antigenic re-stimulation. These cells would have an improved capacity to expand and
persist and control tumor in vivo after transfer. In contrast, the traditional expansion
approach can lead to the overgrowth of CD4+ T-cells or the expansion of CD8+ cells
that lose CD28, are low in bcl-2 and other survival and memory markers, and are
hypo-responsive to antigenic re-stimulation. These cells are postulated to have poorer
persistence with many of them undergoing apoptosis or anergy in vivo. We also
propose that 4-1BB agonists at low dose may provide a further boost to the infused
TIL, perhaps even rescuing cells that would have been otherwise deleted after antigen
contact in vivo due to lack of adequate co-stimulation.

Reprinted with permission from: Chacon JA, Pilon-Thomas S, Sarnaik AA,
Radvanyi LG. Oncoimmunology. 2013 Sep 1;2(9):e25581.

- 187 -

Figure 5.1. Proposed model for the role of 4-1BB co-stimulation during TIL
expansion and TIL therapy in vivo.
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5.2 Future Directions
Although we have demonstrated one way in which the TIL can become
activated within the tumor microenvironment, further studies need to be carried out in
understanding the role of negative cells and factors that could cause the TIL to
undergo apoptosis and not migrate out of the tumor fragment. We did not investigate
the role of the melanoma tumor cells, but they could play a key role in suppressing
TIL proliferation. Other negative cells and factors within the tumor
microenvironment could be T regulatory cells, Myeloid Derived Suppressor Cells,
Transcription growth factor-β (TGF- β), and PD-1, PD-L1. These cells and factors
could potentially decrease the TIL from migrating out of the tumor and proliferating.
Investigating ways to overcome these negative barriers within the tumor
microenvironment would allow researchers to find new approaches to isolate and
expand the TIL during the initial phase of ACT. By targeting negative factors within
the tumor fragment, this could potentially lead to expanding TIL from more patients
and an increase in the patients eligible to undergo the secondary expansion phase.
In addition, our initial observation using anti-CTLA-4 to initially expand the
TIL was that anti-CTLA-4 preferentially expanded the CD4+ TIL. However, studies
have suggested that the combination of anti-CTLA-4 and anti-4-1BB mediate the
rejection of B16 melanoma tumors in a mouse model (138). Combining anti-4-1BB
with other co-stimulatory molecules, such as OX40 could have potential in expanding
the TIL during the initial TIL isolation and/or during the secondary expansion. We
have previously observed that using an agonistic anti-OX40 antibody (Dr. Andrew
Weinberg lab) to expand the TIL during the REP expanding the CD4+ TIL, compared
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to the anti-4-1BB antibody that expanded a CD8+ TIL population. Although the
specific role of CD4+ TIL has not been thoroughly investigated, there are a number of
antigens that contain HLA class II-restricted epitopes, such as tyrosinase, NY-ESO-1
and MAGE-1 (48, 60, 66). Clinical trials have been conducted and have shown
promising results using antigen-specific CD4+ cells to treat metastatic melanoma
patients (48, 60, 66). These trials demonstrate that CD4+ T cells do play a role for the
treatment of melanoma. The exact role of CD4+ TIL needs to be elucidated and
thoroughly investigated. There could be a number of different subsets of CD4+ T cells
(Th1, Th2, and Th17) within the TIL population (67, 139). These different subsets
could play key roles in ACT and secrete different cytokines that could modulate a
tumor response.
The standard protocol to expand TIL used during ACT is to use the cytokine
IL-2. However, IL-2 can drive the TIL towards differentiation (76). Further studies
should investigate whether using lower doses of IL-2 with or without addition of anti4-1BB antibody can induce a similar effector phenotype and function, without
decreasing the levels of CD27 in the CD8+ subset during initial TIL isolation. Studies
have suggested that resting the TIL after expansion can induce an increase in CD27
levels (121, 140) but future work needs to done to investigate whether this occurs in
our cultures after 4-1BB activation. IL-15 is another member of the common gamma
chain family. IL-15 has also been shown to induce 4-1BB on CD44high CD8+ memory
cells (141).
During the secondary expansion phase of the TIL (REP), irradiated PBMCs
from 6 normal donors act as ‘feeder cells.’ The feeder cells secrete cytokines and are
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a mix of different cells within the population of normal donor PBMCs. However,
sometimes we encounter technical issues with the feeder cells. Although we pool 6
normal donor PBMCs, and irradiate them prior to culturing these cells with the TIL,
the TIL do not always expand. The exact mechanism of what exactly the feeder cells
are doing to activate the TIL is still not clear. We presume that the anti-CD3
crosslinks with the Fc portions on the feeder cells and this activates the TIL. However,
we do not know for sure if this is occurring. The feeder cells may also be a source for
some growth factors, anti-oxidants, and co-stimulatory factors for TIL expansion;
although we found that the feeder cells had very little expression of 4-1BB and 41BBL (90). We did not dissect the different subsets of cells that are within the feeder
population. In addition, this may be difficult to do since we pool 6 normal donor
PBMCs to set up the REP. We pool 6 normal donor PBMCs in order to have a large
heterogeneous population of feeder cells. It would be interesting to determine what
subsets within the PBMC population and/or cytokines initiate the outgrowth of the
TIL. In addition, there may be some suppressor factors in the PBMCs that may induce
poor expansion of the TIL. This needs to be further investigated.
Another factor that needs further investigation is the persistence of the TIL in
vivo. Our preliminary data used an NSG mouse model to investigate the persistence
and anti-tumor activity of the TIL expanded with or without the anti-4-1BB antibody.
Our data demonstrated that the TIL expanded with the anti-4-1BB antibody exhibited
better persistence and anti-tumor activity. However, the differentiation stage of T
cells may influence where they traffic in vivo. Naïve and central memory T cells
traffic primarily to the secondary lymphoid structures spleen and lymph nodes
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seeking out antigen, whereas effector memory T cells traffic to peripheral places,
such as the lung and blood (73, 74, 78, 142, 143). Studies also suggest that central
memory cells are the cells that persist in vivo (73, 74, 78, 142, 144), however it is the
effector cells that initiate the anti-tumor responses. It would be interesting to
determine if expanding the TIL with the anti-4-1BB antibody for a shorter period of
time during the initial isolation period or in a lower dose of IL-2 helped the TIL
persist in vivo. Our mouse studies ended after only a week but it would be interesting
to see if we can detect the persistence of the TIL after a longer period. In addition,
studies directly injecting the anti-4-1BB antibody into mice or humans have shown
promise. However, the concentration of the anti-4-1BB antibody needs to be carefully
monitored as continuous injections of anti-4-1BB antibody in a clinical trial treating
melanoma patients induced toxicity of the liver, resulting in the trial to shut down
(145, 146). This was believed to be caused by NK cells in the liver that expressed
high levels of 4-1BB (145, 146). In our previous studies, we have also found that
even using anti-4-1BB antibodies in an in vitro system has to be carefully monitored.
We found that when 10ng/ml of anti-4-1BB was coated on a plate, the anti-4-1BB
protected post-REP TIL from activation-induced cell death (AICD) (90). However,
when we used a higher concentration (100ng/ml), we found that the anti-4-1BB
antibody reversed its protective effect against AICD in the post-REP TIL (90). As
mentioned previously, a number of cells within the body express 4-1BB. Therefore,
when the anti-4-1BB antibody is given to mice or patients systemically, it may have
off-target effects on cells that express high levels of 4-1BB, creating too much costimulation.
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We observed that when we initially set up the fragments with or without the
anti-4-1BB antibody, the cells that received the anti-4-1BB antibody exhibited an
increase in pro-inflammatory cytokines (Figure 3.9). IL-6 is an important cytokine
that has been demonstrated to regulate dendritic cell differentiation (147). Therefore,
we wanted to investigate what the role of IL-6 was in the melanoma tumor fragment.
We set up initial experiments investigating what the effects would be if we
neutralized or activated IL-6. The addition of IL-6 (IL-6+) abrogated the CD8+
percentage. The effect of IL-6 had an opposite effect in the dendritic cells within the
fragment. The activating IL-6 antibody (IL-6+) had a positive effect on the dendritic
cells, increasing the IFN-gamma producing cells, NFB, and MHC-II (Figure 5.2A).
We found that when IL-6 was neutralized, (IL-6 (-)), this increased the TIL to
increase percentage of CD8, IFN-gamma, NFB, Ki67, and decreased IB (Figure
5.2B). We believe that the effect of IL-6 could be a two-edged sword. Although IL-6
seems to play a positive role on the dendritic cell population, it appears to abrogate to
the CD8+ T-cell subset. Other cells within the microenvironment secrete IL-6, such as
myeloid derived suppressor cells (MDSCs). MDSC could also play a role in
suppressing the T cells from migrating out of the fragment. MDSCs can inhibit Tcells
through blocking the translation of the T-cell zeta chain (148, 149), and promoting Tcell apoptosis. It would be interesting to investigate the role of anti-4-1BB antibody in
the MDSC and determine whether the MDSCs are the main population secreting IL-6
and whether anti-4-1BB antibody could augment their suppressive factors. Another
population that may be affecting the T cells are macrophages. There are 2 subsets of
macrophages, M1 and M2. M1 macrophages are pro-inflammatory producing TNF-
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alpha, IL-23, and IL-6 (148, 149). On the other hand, M2 macrophages are antiinflammatory, and become activated by IL-6 production. It would interesting to
investigate whether the different subsets of macrophages are present within the
melanoma tumor fragment, how they would affect the TIL, and what role 4-1BB
activation may have on the macrophage subsets, if they are present within the
melanoma tumor fragment.
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Figure 5.2. Modulation of Dendritic cells and T cells within melanoma fragments
with IL-6. The melanoma tumor was cut up into multiple fragments and placed in
culture with IL-2±anti-4-1BB antibody. In addition, a neutralizing (-) or activating (+)
IL-6 cytokine was added to the cultures. When we investigated the effect of IL-6 in
the dendritic cell subset, we found that adding an activating IL-6 cytokine (+)
increased the dendritic cell IFN-gamma production, NFB, and MHC-II (A). We
found that neutralizing IL-6 (-) increased the proliferation, CD8 percentage and
NFB within the T cells subset. This effect was reversed when an activating IL-6
cytokine was added to the cultures (B). 
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Figure 5.2. Modulation of Dendritic cells and T cells within melanoma fragments
with IL-6.
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Materials and Methods
Reagents
A fully human and purified IgG4 monoclonal antibody (mAb) against human CD137
(BMS-663513; Lot 6A20377) was kindly provided by Bristol Myers Squibb (BMS;
Princeton, NJ) through a Materials Transfer Agreement . BMS-663513 (henceforth
called anti-4-1BB) was stored at 4ºC at a concentration of 14.9 mg/ml and was
certified to have <0.5 EU/mg endotoxin level, >95% purity, and <5% high molecular
weight species. Human recombinant IL-2 (Proleukin™) was generously provided by
Prometheus Therapeutics and Diagnostics (San Diego, CA). Flow cytometry reagents
were obtained from BD Biosciences, eBioscience, or BioLegend.
Isolation and expansion of TIL from human melanoma patient tumors
Melanoma tumors were surgically resected from stage III-IV melanoma patients. The
tumor was then cut up into 3-5mm2 fragments using a sterile scalpel. The fragments
were placed in a 24 well plate with TIL culture media (TIL-CM) and 6,000 IU/ml
Interleukin-2 (IL-2) in order to help the TIL grow out of the fragment. The TIL-CM
contained RPMI 1640 with Glutamax (Gibco/Invitrogen; Carlsbad, CA), 1X PenStrep (Gibco/ Invitrogen; Carlsbad, CA), 50µm 2-mercaptoethanol (Gibco/ Invitrogen;
Carlsbad, CA), 20µg/ml Gentamicin (Gibco/ Invitrogen; Carlsbad, CA), and 1mM
pyruvate (Gibco/ Invitrogen; Carlsbad, CA). Each well had 1 fragment and the
fragments were kept in culture for a period of 3 weeks. After the 3 week period, the
TIL were referred to as Pre-Rapid Expansion (pre-REP) TIL. For our control cultures,
the fragments were placed in 6,000IU/ml IL-2 with a fully-human IgG4 Isotype
control (Eureka therapeutics ET904).
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Rapid expansion protocol (REP)
The REP was performed in upright T-25 flasks by activating 1.3 x 105 pre-REP TIL
with 26 x 106 allogeneic, irradiated (5,000cGy) PBMC feeder cells with 30 ng/ml
OKT3 (anti-CD3; Abbott Labs, Abbott Park, IL) in 1:1 mixture of TIL-CM and AIMV (Invitrogen). Exogenous anti-4-1BB was added to some of the flasks at different
concentrations on day 0 of the REP. On day 2 of the REP, 6,000 IU/ml IL-2 was
added to each flask. The TIL were expanded for another 12 days. On days 5, 7, 9,
and 12 of the REP, the TIL were diluted as necessary with a 1:1 ratio of TIL-CM and
AIM-V with a final concentration of 6,000 IU/ml IL-2 to keep the cells between 1-2 x
106/ml.
Fragment flow cytometry staining
The melanoma fragment was cut up into 3-5 mm2 pieces and mechanically
disintegrated using glass slides, re-suspended in 2 ml sterile FACS Wash Buffer
(FWB) and washed for 5min at 1400rpm. The FWB contained 1X Dulbecco’s
Phosphate Buffered Saline (D-PBS) and 1% Bovine Serum Albumin (BSA (Sigma
Aldrich)). The fragment was then stained for fluorochrome-conjugated monoclonal
antibodies that recognized surface markers CD11c, CD80, CD86, 4-1BB, 4-1BBL,
HLA-DR, CD3, CD8, CD56, CD19, CD20, CD4, (eBioscience, BD Biosciences, and
BD Pharmingen) and live/dead fixable dye (Molecular Probes by Life Technologies;
Lot 1413034) in 0.1ml FACS Stain Buffer (FSB) for 25 minutes on ice. The FSB
contained 1X D-PBS, 1% BSA, and 5% goat serum. The cells were then washed in
FWB for 5 minutes at 1400rpm and fixed in 1X D-PBS, 1% para-formaldehyde
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solution. The cells were then acquired using a BD FACScanto II flow cytometer
machine using FACSDiva software.
TIL flow cytometry staining after 1 week in culture
One week after the fragments were set up with or without the anti-4-1BB antibody,
the fragment was mechanically disaggregated, filtered, and washed with FWB for 5
minutes at 1400rpm. The cells that grew out of the fragment were also collected and
re-suspended in 2ml FWB and washed for 5min at 1400rpm. The cells were then
stained for fluorochrome-conjugated antibodies that recognized surface markers CD3,
CD8, CD56, CD4, CD11c, HLA-DR, CD80, CD86, CD56, and 4-1BB (eBiosciences,
BD Pharmingen, and BD Biosciences). A live/dead fixable dye (Molecular Probes by
Life Technologies; Lot 1413034) was also used to gate out dead cells when acquiring
the samples. The samples were stained in FWB for 25 minutes on ice. After, the
samples were washed in 2ml FWB for 5 minutes at 1400rpm and fixed in 1X D-PBS,
1% para-formaldehyde solution. The samples were acquired using a BD FACScanto
II flow cytometer machine.
TIL staining using flow cytometry after 3 weeks in culture
Fragments from melanoma tumors were set up as described earlier with or without
the addition of agonistic anti-4-1BB antibody. After 3 weeks in culture, the TIL were
harvested and stained for surface and intracellular markers using flow cytometry.
Briefly, pre-REP TIL were harvested, counted, and washed with 2ml FWB for 5
minutes at 1400rpm.,The cells were stained with surface markers CD3, CD4, CD27,
CD28, and CD8 (eBiosciences, BD Pharmingen, and BD Biosciences). The viability
dye AmCyan Aqua (Molecular Probes by Life Technologies) was also used to help
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gate out dead cells while acquiring our samples. The cells were stained in FSB for 25
minutes on ice. After, the cells were washed with 2ml FWB and BD
Cytofix/Cytoperm Fixation and Permeabilization Solution (BD Biosciences Cat:
554722) was added to the samples for 20 minutes at room temperature in the dark.
After, the cells were washed with 1X BD Perm/Wash Buffer (Cat: 554723) for 5
minutes at 1400rpm, followed by intracellularly staining for Granzyme B, Perforin
and EOMES (eBiosciences, BD Biosciences) in 1X Fixation Buffer for 25 minutes on
ice. After, the samples were washed with FWB for 5 minutes at 1400rpm and fixed in
1X D-PBS, 1% para-formaldehyde solution. The samples were acquired using a BD
FACScanto II flow cytometer machine. In some cases, harvested cells after 3 weeks
of culture were stained for cell surface markers together with a MART-1 peptide
HLA-A0201 tetramer (Beckman-Coulter) to enumerate the frequency of CD8+
MART-1-specific T cells.
Cytospin and Immunocytochemistry staining for surface and nuclear markers
The fragments were set up as previously mentioned earlier with or without anti-41BB antibody. After 1 week in culture, the cells were collected and washed twice in
1X D-PBS for 5 minutes at 1400rpm. After, the cells were re-suspended in 1ml 4%
para-formaldehyde for 20 minutes at room temperature. The cells were washed again
in 1X D-PBS and re-suspend in 1ml and placed at 4°C. After, the cells were cytospun
onto glass slides at 750 rpm for 3 minutes using Shandon Cytospin II centrifuge. The
samples for Ki67 (Dako) and NFκB (p65) (BD transduction laboratories) (nuclear
staining) were placed in 0.2% PBS Triton-X solution for 10 min at room temperature
(RT). After, the nuclear staining samples were washed in 1X D-PBS 3 times. All
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samples were then placed in 3% H2O2/methanol for 10 minutes at RT to block
endogenic peroxidase. The samples were then washed 3 times in 1X D-PBS and
2.5% normal horse serum (Vectastain Universal Elite ABC Kit) was added to all
slides for 30 minutes in a humid chamber at RT. After, the primary antibody was
added and kept at 4°C overnight. The next day, a biotinylated secondary antibody was
added to the samples for 30 min at RT (Vectastain Universal Elite ABC Kit). The
slides were then washed 3 times in D-PBS and peroxidasen conjugated avidin biotin
complex ABC Reagent (Vectastain Universal Elite ABC Kit) was added for 30 min at
RT. After, the samples were washed again with D-PBS and 3,3-Diaminobenzidine
(DAB) was added. The samples were then counterstained and covered. Analysis was
done using Leica Application Suite (LAS) V4.2 software (Leica Microsystems). For
NFκB (p65) staining, analysis was also done using the LAS V4.2 software, but
additional analysis was conducted using Vectra Intelligents Slide Analysis System
(Vectra, Perkin Elmer) Nuance software 3.0.1.2, using composite coloring style
“Fluorescence.”
Ki67 staining using flow cytometry in early cultures
The melanoma tumor was cut up into 3-5mm2 fragments and placed in media, IL-2 ±
anti-4-1BB antibody. After 1 week, the cells that migrated out of the fragment were
collected and washed twice in FWB for 5 minutes at 1400rpm at 4°C. The cells were
subsequently stained for cell surface markers CD3 FITC (BD Biosciences; Catalog
number 555916; Lot 17763) and CD8 Pacific Blue (BD Pharmingen; Catalog number
558207; Clone RPA-T8) on ice for 25 minutes. During this time, the fixation buffer
(BD Bioscience; Catalog 554655) was kept in a 37°C water bath and the Perm Buffer
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III (BD Phosflow; Catalog 558050; Lot 2128930) was kept at -20°C. The flow
cytometry tubes were labeled and 1ml fixation buffer was added to each tube. After,
the TIL were added to each tube, re-suspended, and placed at room temperature for
10 minutes. Then, the cells were spun in FWB for 5 minutes, 4°C, 1400 rpm.
Afterwards, the supernatant was aspirated and 100ul Perm Buffer III was added to
each tube while vortexing the tube. The tubes were then placed in the dark at room
temperature for 5 minutes. After, the cells were washed in 1 ml stain buffer for 5
minutes at 1400 rpm at 4°C. The Ki67 antibody (BD Pharmingen; Catalog 561284)
was then added to each tube and the tubes were subsequently left in the dark at room
temperature for 1 hour. The cells were then washed with 3 ml FWB for 5 minutes at
1400rpm at 4°C. The cells were then re-suspended with 300µl staining buffer and the
samples were acquired using a BD FACScanto II flow cytometer machine.
NFκB, and IκBα staining using flow cytometry in early cultures
The melanoma tumor was cut up into multiple fragments, placed in TIL-CM, IL-2 ±
anti-4-1BB antibody. After 1 week, the fragment and the cells that migrated out of the
tumor fragment were harvested. The fragments were mechanically disaggregated and
filtered. The fragments and the cells that migrated out of the fragment were washed
with FWB and subsequently stained for cell surface markers CD3 FITC (BD
Biosciences; Catalog number 555916; Lot 17763) and CD8 Pacific Blue (BD
Pharmingen; Catalog number 558207; Clone RPA-T8) on ice for 25 minutes. During
this time, the Perm Buffer III was placed at -20°C and the fixation buffer was placed
in a 37°C water bath. After the surface staining was done, the cells were washed in
2ml FWB two times. The supernatant was aspirated and 1 ml fixation buffer was
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added to each tube and the tubes were placed at room temperature for 20 minutes.
After 20 minutes, the cells were washed with FWB for 5 minutes at 1400rpm, 4°C.
The supernatant was aspirated and 100µl Perm Buffer III was added to each tube
while vortexing each tube. The tubes were then placed on ice for 30 minutes and after
washed twice in 1ml FWB for 5 minutes, 1400rpm, 4°C. Afterward, the cells were
then stained using NFκB (p65) (BD Pharmingen; Catalog number 560335) and IB
Alexa 647 (BD Pharmingen; Catalog number 560817) and left in the dark at room
temperature for 1 hour. The cells were then washed with 3ml FWB for 5 minutes,
1400rpm, 4°C, then re-suspended in 300µl FWB and samples were subsequently
acquired using a BD FACScanto II flow cytometer machine.
Staining for Interferon-gamma and degranulation (CD107a) in the TIL after 3
week culture period
Melanoma tumors were surgically resected, cut up into multiple fragments, and
placed in culture with TIL media, IL-2, with or without the addition of an anti-4-1BB
antibody. After 3 weeks, the TIL were set up at a 1:1 ratio with HLA-matched
melanoma tumor lines in a 96-well plate for 1 hour at 37°C. After, Golgi-Stop (BD
Biosciences Catalog 554724) was added to each well and the cultures were left at
37°C for a 5 hour period. During this time, CD107a antibody (BD Biosciences) was
also added to each condition. After 5 hours, the cells were harvested, washed with
FWB for 5 minutes at 4°C. The cells were then stained for surface markers CD3 and
CD8 for 25 minutes at 4°C. After, the cells were washed with FWB again, resuspended in fixation buffer (added while vortexing the tubes) and incubated for 15
minutes at room temperature. After, the cells were washed with FWB and re-

- 204 -

suspended in Cytofix/Cytoperm buffer and incubated at room temperature for 20
minutes. The cells were then washed with FWB and stained for IFN-gamma for 25
minutes in 4°C. The cells were then washed again and the samples were acquired
using a BD FACScanto II flow cytometer machine.
Intracellular phosho-staining in pre-REP TIL
The melanoma tumors were cut up into multiple fragments and placed in a 24-well
plate with TIL-CM, IL-2 ± anti-4-1BB antibody. After 3 weeks, the TIL were
harvested, washed twice in media for 5 minutes at 1400rpm at 4°C. After, 250,000
TIL per well were placed in a 48-well plate and kept at 37°C for 3-4 hours. During
this incubation period, fixation buffer (BD Bioscience; Catalog 554655) was kept in a
37°C water bath and the Perm Buffer III (BD Phosflow; Catalog 558050; Lot
2128930) was kept at -20°C. After the 3-4 hour incubation period, 200 IU/ml IL-2
was added to the cultures. As a control, half the cultures were not given IL-2. The
plate was then placed in 37°C for 20 minutes. The flow cytometry tubes were labeled
and 1ml fixation buffer was added to each tube. The TIL were then added to the tubes,
re-suspended and placed in 37°C incubator for 10 minutes. After 10 minutes, the cells
were spun for 5 minutes at 1400rpm at 4°C. After the wash, the supernatant was
aspirated and 1ml Perm Buffer III was added to the tubes, re-suspended and placed in
4°C for 20 minutes. The cells were then washed twice in 1ml stain buffer for 5
minutes at 1400rpm, 4°C. After, the antibodies (CD8, pSTAT5, CD3, pAKT) were
added to the tubes to a total volume of 100ul and left in the dark for 30 minutes at
room temperature. After 30 minutes, the cells were washed with 3ml stain buffer for 5
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minutes, 1400rpm at 4°C, then re-suspended with 300ul stain buffer and the samples
were acquired using a BD FACScanto II flow cytometer machine.
Staining for bcl-6 in pre-REP TIL
The fragments were set up as previously described with TIL-CM, IL-2 ± anti-4-1BB
antibody. After 3 weeks, the TIL were harvested, washed with 2ml FWB at 1400rpm
for 5 minutes, and after stained for surface makers CD3 FITC and CD8 Pacific Blue
for 25 minutes on ice. During this time, the Perm Buffer III was kept at 20°C and the
fixation buffer was kept in a 37°C water bath. After the 25 minute incubation period,
the cells were washed twice in FWB and the cells were fixed in 200ul fixation buffer
for 10 minutes at 37°C. The cells were then washed in 2ml 1X-DPS at 4°C, 1400rpm
for 5 minutes. The supernatant was then aspirated and the cells were permeabilized
using 100ul of the pre-chilled Perm-Buffer III. The cells were then incubated on ice
for 30 minutes. After, the cells were washed twice with BD stain buffer and after resuspended in 100µl FWB containing bcl-6 PerCP-Cy5.5 (BD Pharmingen; catalog
number 562198) for 45 minutes at room temperature. The cells were subsequently
washed and acquired using a BD FACScanto II flow cytometer machine.
Measurement of pro-inflammatory cytokines using Meso-Scale Discovery assay
The melanoma tumors were surgically resected. The tumors were then cut up into
multiple fragments and placed in culture with TIL media, IL-2± anti-4-1BB antibody.
After 4 days, the supernatant was collected from each condition. The proinflammatory cytokines were measured using a V-plex custom human cytokine kit
(Meso-Scale Discovery, Rockville, MD).
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IFN-gamma measurement using Enzyme Linked Immunosorbent Assay (ELISA)
for pre-REP TIL
After 3 weeks in culture, the pre-REP TIL were co-cultured at a 1:1 ratio with
autologous or HLA-matched target cells and placed at 37°C overnight. The samples
were added in triplicate with 100µl added to each well in a 96 round bottom plate.
The supernatants were collected after 24hr and IFN-gamma secretion was measured
using a human IFN-gamma ELISA kit (Thermo Scientific KB132422). A 96-well
ELISA plate reader (ELx808, Bio-Tek Instruments Inc., Houston, TX) was used to
read the plate.
Flow cytometric analysis of post-REP TIL
Pre-REP and post-REP TIL were washed with FACS Wash Buffer (FWB) that
contained Dulbecco’s Phosphate Buffered Saline 1X (D-PBS; Gibco/Invitrogen) and
1% Bovine Serum Albumin (BSA). The cells were resuspended in 0.1 ml FACS
Staining Buffer (FSB) consisting of 1X D-PBS, 1% BSA, and 5% goat serum and
stained on ice for 20 min using fluorochrome-conjugated monoclonal antibodies
recognizing the following surface and intracellular markers: CD8, CD4, CD27, CD28,
KLRG-1, Eomesodermin, Granzyme B (GB), and Perforin (Perf). The TIL were
washed with FWB and re-suspended in 0.3 ml 1X D-PBS, 1% para-formaldehyde
solution. The stained cells were analyzed using the BD FACScanto II flow cytometry
analyzer using FACSDiva software. The data was later analyzed using FlowJo
software (TreeStar).
Analysis of 4-1BB and 4-1BBL expression during the REP
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Pre-REP TIL were labeled with 1 μM CFSE (Molecular Probes-Invitrogen, Carlsbad,
CA) in order to be able to distinguish the TIL from the irradiated PBMC. The REP
was then set-up as described above. On day 1 and day 2, the cells were harvested
from the REP and stained for CD8, CD3, 4-1BB, and 4-1BBL (BD Biosciences).
Gating was done on the viable cell population and then on the CFSE-positive (TIL) or
CFSE-negative (feeders) population. The different populations were then analyzed for
their expression of 4-1BB and 4-1BBL.
Flow cytometric sorting of post-REP CD8+ TIL
Post-REP TIL were harvested, washed, and re-suspended at 25 x 106/ml in 2 ml of
sterile FSB.

The cells were stained using anti-CD8-Pacific Blue on ice for 20

minutes, washed, re-suspended in sterile FWB, and the CD8+ subset isolated by
sorting in a FACSAria sorter (BD Biosciences, San Jose, CA). The sorted cells were
washed in cold FWB and rested for 3 hours in order to shed the antibody. Afterwards,
RNA was isolated from the sorted TIL for quantitative real-time PCR (qRT-PCR)
analysis and/or cytotoxic T-cell assay.
Quantitative real-time PCR
We used quantitative real-time PCR (qRT-PCR) to measure the expression of antiapoptotic genes Bcl-2 and Bcl-xL or pro-apoptotic gene Bim. RNA was isolated from
5 x 106 post-cells on day 14 of the REP (post-REP cells) using the Qiagen RNeasy
Mini Kit (Qiagen; Duesseldorf, Germany). By this time no remaining irradiated
PBMC feeder cells were left in the cultures . RNA quantity and was determined
using a NanoDrop spectrophotometer (Thermo Scientific; Wilmington, DE). The
RNA was then subjected to qRT-PCR analysis as previously described . The
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following

primer

sequences

were

used;

forward

bcl-2:

primer:

5’-

CAGAAGGGACTGAATCGGAG-3’, reverse primer: 5’-TGGGATGTCAGGTCA
CTGAA-3’; bcl-xL: forward primer: 5'-TGAGTCGGATCGCAGC TTGG-3’, reverse
primer:

5'-TGGATGGTCAGTGTCTGGTC-3’;

ACAGGAGCC

CAGCACCCATG-3’,

ACGCCGCAACTCTTGGGCGA-3’;

and

TTGCCGACAGGATGCAGAA-3’,

bim:

forward

reverse
β-actin:
reverse

primer:

primer:

forward

primer:

primer:

55'5'5'

GCCGATCCACACGGAGTACT-3’.
Cytotoxic T-cell assay
TIL from HLA-A0201+ patients having a significant pre-REP CD8+ T-cell population
recognizing the Melan-A/MART-1 peptide (ELAGIGILTV), as determined using
HLA-A0201-peptide tetramer staining, were subjected to the REP with or without
added anti-4-1BB on day 0. The post-REP cells were sorted for CD8+ T cells and
evaluated for their cytolytic function using a caspase-3 cleavage CTL assay as
previously described . The target cells included HLA-A0201+ 624 melanoma cells or
MART-1 peptide-pulsed T2 human lymphoma cells. The HLA-A unmatched
melanoma cell line 938 and T2 cells pulsed with a human immunodeficiency virus
rev peptide (ILKEPVHGV) were used as controls. The target cells were labeled with
DDAO-SE (Molecule Probes-Invitrogen) for 15 min at 37°C. The sorted TIL and
target cells were incubated at different effector-to-target ratios, as indicated for 3-4 h
at 37°C before harvesting and staining for cleaved caspase 3 in the target cells .
Multiplex cytokine assay
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Post-REP TIL were harvested and washed twice in TIL-CM to remove any excess IL2 and plated for 24 h in a 96 well plates pre-coated with or without 10 ng/ml antiCD3. The supernatants were collected and cytokine secretion was measured using a
Luminex-100 system using beads recognizing IL-2, IFN-γ, and TNF-α, (Millipore,
Billerica, MA). The net cytokine levels after subtraction of control wells without
anti-CD3 were determined.
Cell survival assays post-REP
Post-REP TIL were harvested, washed twice in TIL-CM, and re-cultured in a 24 well
plates at 400,000 cells per well in 2-ml TIL-CM with no cytokine or 200 IU/ml IL-2.
After 4 days, the cells were harvested and stained with anti-CD8, 7-AAD, and
Annexin-V, as described previously .

The stained cells were acquired using a

FACSCanto II flow cytometer. The samples were analyzed by first gating on the live
population. The percentage of CD8+ cells and AnnexinV+ was determined. Viable
cell counts were performed using a hemocytometer and used to calculate the total
number of live CD8+ T cells in the cultures using the percentage of live CD8+ T cells
found by flow cytometry.
Re-stimulation of post-REP TIL with MART-1 peptide-pulsed dendritic cells
Post-REP TIL from HLA-A0201+ patients having at least 0.5% of the CD8+ T cells
staining positive for MART-1 tetramer (ELAGIGILTV) peptide were re-stimulated
for 7 days with mature HLA-A0201-matched DC pulsed with the same MART-1
peptide (ELAGIGILTV), as described previously .

Dendritic cells (DCs) were

generated from adherent monocytes from HLA-A0201+ normal donors using GMCSF and IL-4 for 5 days following by incubation with IL-1β, TNF-α, IL-6, and PGE2
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for 2 days . The mature DCs were isolated, pulsed with MART-1 peptide for 90 min
and then washed. Post-REP TIL were isolated and washed in TIL-CM two times and
rested in TIL-CM for 6 hours without any additional cytokine. The cells were labeled
with the cell division dye eFluor670 (Invitrogen) according to the manufacturer’s
instructions and washed. The labeled TIL and peptide-pulsed DCs were mixed in 24wells at a 10:1 ratio (2 x 106 TIL plus 0.2 x 106 DCs). IL-2 (100 IU/ml) was added to
all cultures to facilitate TIL viability. After 7 days, the cells were stained for CD8
and MART-1 tetramer and analyzed for cell division using a FACSCanto II (BD
Biosciences).
Polymerase chain reaction (PCR)
PCR was performed using a panel of optimized primers specific for 24 members of
the TCRVβ family. Briefly, RNA was extracted from 1 × 106 pre-REP TIL using
Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The
TIL then underwent the REP with or without the addition of anti-4-1BB. RNA was
then isolated the same way on the post-REP TIL. The extracted RNA (1 μg) was
treated with DNAse (Ambion, Austin, TX) to remove contaminating genomic DNA.
All of the DNAse-treated RNA was used to synthesize cDNA by reverse transcription
using the manufacturer's protocol with the SuperScript™ III Reverse Transcriptase
(Invitrogen). PCR was then performed by combining 0.5 μM of one Vβ primer for
each of the different TCRVβ families with 0.5 μM of a Cβ primer, which was used
for each of the 24 reactions. The PCR products were visualized on a 1.5% agarose gel.
TCR Vβ spectratype analysis
For TCR Vβ spectratype analysis, PCR products were diluted in nuclease-free water
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so that 1.5 ng of the PCR product from each TCR Vβ family was subjected to
capillary electrophoresis using an OpenGene™ System (Bayer, Terrytown, NY).
Because the positions of the 5′Vβ and the 3′Cβ primers are fixed, variation in length
of the PCR fragments within any TCR Vβ family is due to differences in length of the
CDR3 regions. Data are presented as fluorescence intensity versus DNA fragment
length. The TCR Vβ10 and Vβ19 families are pseudogenes and were therefore
excluded from analysis. The number of CDR3 sequence peaks were plotted for each
major Vβ family.
In vivo mice experiments
The melanoma tumor was cut up into multiple fragments and placed in TIL-CM and
IL-2 for a period of 4-5 weeks. After, the pre-REP TIL underwent the REP for 2
weeks. The REP was set up with IL-2 alone or IL-2+anti-4-1BB antibody (500ng/ml
on day 0) The NOD/SCIDγc-/- (NSG) mice were kindly provided to us by Dr.
Laurence Cooper (UT MD Anderson Cancer Center, Houston TX). Each experiment
contained 4, 10-12 week-old female mice per condition. We subcutaneously injected
1x106 human melanoma cell line WM35. After 1 week. We intravenously injected
25x106 post-REP TIL through the tail vein that were expanded with IL-2 alone or IL2+anti-4-1BB antibody. During a 7 day period, the tumor sizes were monitored using
calipers. After 1 week of the post-REP TIL being injected in the NSG mice, the mice
were sacrificed using CO2 and cervical dislocation. The blood, spleens, and lungs
were harvested, filtered, washed with FWB twice and stained for human surface
markers, CD45, CD4, CD3, and CD8 Pacific Blue for 10 minutes at room
temperature. After, 100µl Cal-Lyse lysing solution was added to each tube. The cells
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were incubated in the dark for 10 minutes at room temperature. Prior to acquiring our
samples using a BD FACScanto II flow cytometer machine, we added 100µl of
AccuCheck counting beads (Invitrogen/Molecular Probes; Product code PCB100) to
each tube of lysed cells.
*The final Absolute Count=(Number of cells counted/ total number of beads counted
(A+B) x Number of beads per µl (known concentration)
*Reprinted from:
http://tools.lifetechnologies.com/content/sfs/manuals/L20054_Rev0809.pdf
Statistical Analysis
Statistical analysis for comparison of 2 groups was done using the Wilcoxon signed
rank test or Student’s t test (paired datasets), or the Wilcoxon rank sum test (unpaired
datasets). Analysis of experiments with 3 or more treatment groups was done using
the one-way or two-way analysis of variance (ANOVA), with Bonferroni post-tests
with both tests using biological relevance occurring when p< 0.05.
analysis was done using Graph Pad Prism (La Jolla, CA).
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